US20200056248A1 - Method for sorting tissue cells - Google Patents
Method for sorting tissue cells Download PDFInfo
- Publication number
- US20200056248A1 US20200056248A1 US16/660,333 US201916660333A US2020056248A1 US 20200056248 A1 US20200056248 A1 US 20200056248A1 US 201916660333 A US201916660333 A US 201916660333A US 2020056248 A1 US2020056248 A1 US 2020056248A1
- Authority
- US
- United States
- Prior art keywords
- cell
- cells
- mirna
- mir
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 210000004027 cell Anatomy 0.000 claims abstract description 365
- 239000002679 microRNA Substances 0.000 claims abstract description 140
- 108091070501 miRNA Proteins 0.000 claims abstract description 137
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 109
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 48
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 162
- 239000003550 marker Substances 0.000 claims description 64
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108091026890 Coding region Proteins 0.000 claims description 18
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 18
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims description 18
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims description 18
- 230000001939 inductive effect Effects 0.000 claims description 16
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 238000013519 translation Methods 0.000 claims description 10
- 206010059866 Drug resistance Diseases 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 59
- 210000002889 endothelial cell Anatomy 0.000 abstract description 37
- 229940125396 insulin Drugs 0.000 abstract description 30
- 102000004877 Insulin Human genes 0.000 abstract description 29
- 108090001061 Insulin Proteins 0.000 abstract description 29
- 108091023084 miR-126 stem-loop Proteins 0.000 description 41
- 108091065272 miR-126-1 stem-loop Proteins 0.000 description 41
- 108091081187 miR-126-2 stem-loop Proteins 0.000 description 41
- 108091030790 miR-126-3 stem-loop Proteins 0.000 description 41
- 108091092317 miR-126-4 stem-loop Proteins 0.000 description 41
- 210000000130 stem cell Anatomy 0.000 description 26
- 210000001082 somatic cell Anatomy 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 19
- 108020003589 5' Untranslated Regions Proteins 0.000 description 18
- 230000008672 reprogramming Effects 0.000 description 18
- 108091093189 Mir-375 Proteins 0.000 description 15
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 108020005345 3' Untranslated Regions Proteins 0.000 description 13
- 108091092539 MiR-208 Proteins 0.000 description 13
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000004413 cardiac myocyte Anatomy 0.000 description 11
- 108091005948 blue fluorescent proteins Proteins 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 108700026220 vif Genes Proteins 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 229930182816 L-glutamine Natural products 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- -1 miR-196b-5 Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 6
- 102000034287 fluorescent proteins Human genes 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 239000012583 B-27 Supplement Substances 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 4
- 108010060309 Glucuronidase Proteins 0.000 description 4
- 102000053187 Glucuronidase Human genes 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004507 artificial chromosome Anatomy 0.000 description 4
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000001368 germline stem cell Anatomy 0.000 description 4
- 210000000688 human artificial chromosome Anatomy 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 3
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 3
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 3
- 108010023082 activin A Proteins 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108091071651 miR-208 stem-loop Proteins 0.000 description 3
- 108091084446 miR-208a stem-loop Proteins 0.000 description 3
- 108091062547 miR-208a-1 stem-loop Proteins 0.000 description 3
- 108091055375 miR-208a-2 stem-loop Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 102100038511 AT-rich interactive domain-containing protein 3A Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 2
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101000808887 Homo sapiens AT-rich interactive domain-containing protein 3A Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 108091069016 Homo sapiens miR-122 stem-loop Proteins 0.000 description 2
- 108091069085 Homo sapiens miR-126 stem-loop Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 102000004459 Nitroreductase Human genes 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101900150902 Varicella-zoster virus Thymidine kinase Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 108010022164 acetyl-LDL Proteins 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108091064399 miR-10b stem-loop Proteins 0.000 description 2
- 108091062447 miR-10b-1 stem-loop Proteins 0.000 description 2
- 108091092359 miR-10b-2 stem-loop Proteins 0.000 description 2
- 108091041893 miR-10b-3 stem-loop Proteins 0.000 description 2
- 108091069028 miR-10b-4 stem-loop Proteins 0.000 description 2
- 108091086642 miR-216a stem-loop Proteins 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229940028444 muse Drugs 0.000 description 2
- 108020001162 nitroreductase Proteins 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- JUNHQBJCWZVSAT-BQYQJAHWSA-N (e)-n-hydroxy-3-[1-methyl-4-(4-methylbenzoyl)pyrrol-2-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CN(C)C(\C=C\C(=O)NO)=C1 JUNHQBJCWZVSAT-BQYQJAHWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 1
- XVMHQSDMKWQNBK-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=C(F)C=C1 XVMHQSDMKWQNBK-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- QPYLCLZBJGCFNT-VPCXQMTMSA-N C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QPYLCLZBJGCFNT-VPCXQMTMSA-N 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102100033575 Doublesex- and mab-3-related transcription factor B1 Human genes 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102100021008 Endonuclease G, mitochondrial Human genes 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000131390 Glis Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 101000871973 Homo sapiens Doublesex- and mab-3-related transcription factor B1 Proteins 0.000 description 1
- 101000977692 Homo sapiens Iroquois-class homeodomain protein IRX-6 Proteins 0.000 description 1
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 101000857270 Homo sapiens Zinc finger protein GLIS1 Proteins 0.000 description 1
- 108091067631 Homo sapiens miR-10b stem-loop Proteins 0.000 description 1
- 108091067995 Homo sapiens miR-192 stem-loop Proteins 0.000 description 1
- 108091068957 Homo sapiens miR-194-1 stem-loop Proteins 0.000 description 1
- 108091065167 Homo sapiens miR-194-2 stem-loop Proteins 0.000 description 1
- 108091033120 Homo sapiens miR-196b stem-loop Proteins 0.000 description 1
- 108091067578 Homo sapiens miR-215 stem-loop Proteins 0.000 description 1
- 108091067581 Homo sapiens miR-216a stem-loop Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102100023527 Iroquois-class homeodomain protein IRX-6 Human genes 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 description 1
- 101000804949 Mus musculus Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- AOKQNZVJJXPUQA-KQYNXXCUSA-N N(7)-methylguanosine 5'-phosphate Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O AOKQNZVJJXPUQA-KQYNXXCUSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 102100036090 Pituitary homeobox 2 Human genes 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 101710146118 Serine protease HTRA2, mitochondrial Proteins 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102100025883 Zinc finger protein GLIS1 Human genes 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 108010047964 endonuclease G Proteins 0.000 description 1
- 230000030583 endoplasmic reticulum localization Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 108091086416 miR-192 stem-loop Proteins 0.000 description 1
- 108091080253 miR-194-1 stem-loop Proteins 0.000 description 1
- 108091089177 miR-194-2 stem-loop Proteins 0.000 description 1
- 108091088730 miR-215 stem-loop Proteins 0.000 description 1
- 108091072810 miR-294 stem-loop Proteins 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 108091030789 miR-302 stem-loop Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 210000005132 reproductive cell Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention relates to a method for sorting tissue cells, and in particular, relates to a method for sorting an endothelial cell, a hepatocyte, and an insulin-producing cell.
- an object of the present invention is to provide a tool for sorting each type of tissue cell.
- each miRNA-responsive mRNA can be used to allow a type of tissue cell such as an endothelial cell, a hepatocyte, or an insulin-producing cell to be purified with high purity.
- miRNAs expressed specifically in each tissue cell population were identified by microarray analysis.
- an mRNA (miRNA switch) having a marker gene and a target sequence of each of the above miRNAs was constructed.
- this mRNA was introduced into cells that were subject to sorting.
- cells exhibiting different behavior were found to be present.
- these cells were confirmed to be a target type of tissue cell with high purity. In this way, a desired tissue cell sorting method was discovered.
- the present invention has been completed based on such findings.
- the present invention provides the following items.
- a method for sorting an endothelial cell comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- a method for sorting a hepatocyte comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- a method for sorting an insulin-producing cell comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- the miRNA-responsive mRNA comprises a nucleic acid sequence having (i) and (ii) linked in a 5′ to 3′ direction.
- a method for producing endothelial cells comprising:
- an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-126-3P or miR-126-5P and (ii) a nucleic acid corresponding to a coding region of a first marker gene;
- a method for producing hepatocytes comprising:
- an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-122-5P and (ii) a nucleic acid corresponding to a coding region of a first marker gene;
- a method for producing insulin-producing cells comprising:
- an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-375 and (ii) a nucleic acid corresponding to a coding region of a first marker gene;
- the miRNA-responsive mRNA comprises a nucleic acid sequence having (i) and (ii) linked in a 5′ to 3′ direction.
- tissue cells such as endothelial cells, hepatocytes, and insulin-producing cells can be easily sorted and purified to high purity.
- the mRNA that has been introduced into a cell population using the method according to the present invention is only transiently present in cells. Therefore, this makes it possible to sort target cells safely without the mRNA being introduced into the genome.
- the present invention discloses a method in which living cells can be sorted, without fixation, on the basis of the level of expression of an intracellular active miRNA. Further, cells purified in accordance with the method of the present invention can be used for transplantation therapy.
- FIG. 1A shows the results of comparing, using a microarray, the levels of expression of miRNAs between HUVEC and smooth muscle cells (AoSMC) (left panel) or cardiomyocytes (MYH6-EIP4 d20 CMs) (right panel).
- the lower diagram is a Venn diagram showing the analysis results.
- FIG. 1B shows the flow cytometry analysis results obtained after each miRNA switch (containing miR-208, miR-10b-5p, miR-126-3p, miR-126-5p, miR-196b-5, and miR-216a5p) or BFP together with EGFP were introduced into HUVECs.
- FIG. 2A shows the flow cytometry analysis results obtained after each miRNA switch (containing miR-208, miR-10b-5p, miR-126-3p, miR-126-5p, miR-196b-5, or miR-216a5p) together with EGFP was introduced into a cardiomyocyte population containing endothelial cells derived from induced differentiation of iPS cells.
- FIG. 2A also shows the results obtained by gating the cells in each gate above and by staining them with an anti-CD31 antibody.
- the term “negative fraction” means that the results obtained by gating the cells outside the above gate and by staining them with the anti-CD31 antibody.
- FIG. 2B is a graph showing the percentage of CD31-positive cells in cells sorted using each miRNA switch (miR-208, miR-126-3p, and miR-126-5p) from a cardiomyocyte population containing endothelial cells induced from each of iPS cells (201B7, 409B2, and 606A1) and ES cells (KhES1).
- FIG. 2C shows the results of subjecting HUVEC or the cells, which were sorted using miR-126-5p miRNA switch, to tube formation assay.
- FIG. 3A is a schematic diagram illustrating an miRNA switch containing two target sequences.
- FIG. 3B is the flow cytometry analysis results showing the percentage of CD31-positive cells or cTnT-positive cells in cells sorted using each miRNA switch (miR-126-3p+miR-208, miR-126-5p+miR-208, miR-208+miR-126-3p, miR-208+miR-126-5p, and miR-208) from cardiomyocytes and endothelial cells induced from iPS cells.
- 3C has graphs each showing the percentage of CD31-positive cells or cTnT-positive cells in cells sorted using each miRNA switch (miR-126-3p+miR-208, miR-126-5p+miR-208, miR-208+miR-126-3p, miR-208+miR-126-5p, and miR-208) from cardiomyocytes and endothelial cells induced from each of iPS cells (201B7 and 409B2) and ES cells (KhES1).
- miRNA switch miR-126-3p+miR-208, miR-126-5p+miR-208, miR-208+miR-126-3p, miR-208+miR-126-5p, and miR-208 from cardiomyocytes and endothelial cells induced from each of iPS cells (201B7 and 409B2) and ES cells (KhES1).
- FIG. 4A shows the results of comparing, using a microarray, the levels of expression of miRNAs between primary hepatocytes and fibroblasts (NHDF).
- FIG. 4B shows the flow cytometry analysis results obtained after each miRNA switch (containing control, miR-122-3p, miR-122-5p, miR-192-5p, miR-194-5p, and miR-215) together with EGFP was introduced into a hepatocyte population derived from induced differentiation of iPS cells.
- FIG. 5A shows the flow cytometry analysis results obtained after miR-122-5p miRNA switch together with EGFP was introduced into a hepatocyte population derived from induced differentiation of iPS cells.
- FIG. 5A also shows the flow cytometry analysis results obtained by gating the cells in the gate of the left panel, by staining them with an anti-ALUBUMIN or anti-HNF4A antibody, and by performing flow cytometry analysis.
- FIG. 5A shows the flow cytometry analysis results obtained after miR-122-5p miRNA switch together with EGFP was introduced into a hepatocyte population derived from induced differentiation of iPS cells.
- FIG. 5A also shows the flow cytometry analysis results obtained by gating the cells in the gate of the left panel, by staining them with an anti-ALUBUMIN or anti-HNF4A antibody, and by performing flow cytometry analysis.
- 5B is a graph showing the percentage of ALUBUMIN-positive cells or HNF4A-positive cells in: cells sorted using miR-122-5p miRNA switch from a hepatocyte population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-122-5p miRNA switch; and a hepatocyte population (w/o sort) derived from induced differentiation of the iPS cells.
- 5C shows the immunostaining results obtained by staining, with an anti-ALUBUMIN antibody, cells sorted using miR-122-5p miRNA switch from a hepatocyte population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-122-5p miRNA switch; and a hepatocyte population (w/o sort) derived from induced differentiation of the iPS cells.
- FIG. 6A shows the flow cytometry analysis results obtained after miR-375 miRNA switch together with EGFP was introduced into an insulin-producing cell population derived from induced differentiation of iPS cells.
- FIG. 6B is a graph showing the percentage of insulin-positive cells in: cells sorted, using miR-375 miRNA switch from an insulin-producing cell population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-375 miRNA switch; and an insulin-producing cell population (w/o sort) derived from induced differentiation of the iPS cells.
- FIG. 6A shows the flow cytometry analysis results obtained after miR-375 miRNA switch together with EGFP was introduced into an insulin-producing cell population derived from induced differentiation of iPS cells.
- FIG. 6B is a graph showing the percentage of insulin-positive cells in: cells sorted, using miR-375 miRNA switch from an insulin-producing cell population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells
- 6C shows the immunostaining results obtained by staining, with an anti-insulin antibody, cells sorted using miR-375 miRNA switch from an insulin-producing cell population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-375 miRNA switch; and an insulin-producing cell population (w/o sort) derived from induced differentiation of the iPS cells.
- the miRNA-responsive mRNA is also simply called an miRNA switch, and means an mRNA comprising the following nucleic acid sequences (i) and (ii): (i) a nucleic acid sequence specifically recognized by an miRNA; and (ii) a nucleic acid sequence corresponding to a coding region of a first marker gene. (i) The nucleic acid sequence specifically recognized by an miRNA and (ii) the nucleic acid sequence corresponding to a coding region of a first marker gene are operably linked.
- the “miRNA” refers to a non-coding RNA composed of a short chain (20 to 25 bases) that is present in a cell and is participated in the regulation of gene expression through mRNA degradation and/or inhibition of translation from an mRNA to a protein.
- This miRNA is first produced as a transcribed, single-stranded pri-miRNA, an miRNA of which, together with its complementary strand, can form a hairpin loop structure; a portion of the pri-miRNA is cleaved by an enzyme called Drosha present in the nucleus to give a pre-miRNA, which is exported outside the nucleus; and the pre-miRNA is further cleaved by Dicer to become functional.
- the miRNA of (i) can be appropriately selected from an miRNA specifically expressed in a desired type of cell to be sorted.
- the desired type of cell include an endothelial cell, a hepatocyte, and an insulin-producing cell, as described below.
- the miRNA specifically expressed may be miRNAs, the expression levels of which are higher in a desired type of cell than in another type of cell by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more.
- Such an miRNA can be suitably selected from miRNAs registered on database information site (e.g., http://www.mirbase.org/ or http://www.microma.org/) and/or miRNAs described in literature disclosed in the database. Examples include, but are not limited to, miRNAs listed in Table 1.
- miRNAs and the sequences thereof miRNA name miRNA sequence (5′-3′) SEQ ID NO: miR-126-3P ucguaccgugaguaauaaugcg 1 miR-126-5P cauuauuacuuuugguacgcg 2 miR-122-5P uggagugugacaaugguguuug 3 miR-375 uuuguucguucggcucgcguga 4
- the nucleic acid sequence specifically recognized by an miRNA is preferably a sequence perfectly complementary to the miRNA.
- the nucleic acid sequence may have a mismatch in the perfectly complementary sequence as long as the nucleic acid sequence can be recognized by the miRNA.
- the mismatch may be a mismatch that the miRNA can usually recognize.
- the degree of the mismatch may be about 40 to 50%. Examples of such a mismatch include, but are not particularly limited to, 1 base, 2 bases, 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, and 10 bases; or 1% mismatch, 5% mismatch, 10% mismatch, 20% mismatch, 30% mismatch, and 40% mismatch per entire recognition sequence.
- mismatches may be included in the 5′ region of a target sequence, which region is outside a seed region and corresponds to about 16 bases located on the 3′ side of the miRNA.
- the seed region may contain no mismatch or may contain mismatches: 1 base, 2 bases, or 3 bases.
- the length of such a sequence may be a base length corresponding to the number of bases that can bind specifically to RISC.
- the length of the sequence is preferably 18 bases or more and less than 24 bases and more preferably 20 bases or more and less than 22 bases.
- nucleic acid sequence specifically recognized by an miRNA may be used after determined by introducing an miRNA-responsive mRNA having the sequence into a desired type of cell and other cells; and by verifying that expression of a relevant marker gene is inhibited only in the desired type of cell.
- Examples of nucleic acid sequences specifically recognized by miR-126-3P, miR-126-5P, miR-122-5P, and miR-375 include, but are not limited to, target sequences listed in Table 2.
- marker gene refers to a gene encoding any protein that functions as a marker after translation in a cell and enables cell sorting.
- Examples of a gene encoding the protein that functions as a marker after translation in a cell include, but are not limited to, genes encoding fluorescent proteins, light-emitting proteins, chromogenic proteins or fluorescence proteins; genes encoding proteins that help fluorescent proteins, etc., emit fluorescence, light, or color for visualization and quantification; and genes encoding proteins that kill cells when expressed (e.g., a membrane protein-encoding gene, an apoptosis-inducing gene, a suicide gene).
- an apoptosis-inhibiting gene may be used as another marker gene.
- a marker protein refers to a protein translated from an mRNA containing a nucleic acid corresponding to a coding region of the marker gene.
- first is a term used to distinguish between two marker genes when used and is not restricted to a specific marker gene.
- fluorescent protein examples include, but are not limited to, blue fluorescent proteins (e.g., Sirius, BFP, EBFP); cyan fluorescent proteins (e.g., mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, CFP); green fluorescent proteins (e.g., TurboGFP, AcGFP, TagGFP, Azami-Green (e.g., hmAG1), ZsGreen, EmGFP, EGFP, GFP2, HyPer); yellow fluorescent proteins (e.g., TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, mBanana); orange fluorescent proteins (e.g., KusabiraOrange (e.g., hmK02), mOrange); red fluorescent proteins (e.g., TurboRFP, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRe
- examples of the light-emitting protein include, but are not limited to, Aequorin.
- examples of the protein that helps emit fluorescence, light, or color include, but are not limited to, enzymes that degrade fluorescent, light-emitting, or chromogenic precursors (e.g., luciferase, phosphatase, peroxidase, ⁇ -lactamase).
- a relevant precursor is made to contact a cell population or the relevant precursor is introduced into the cell population during target cell sorting.
- the apoptosis-inducing gene means a gene encoding a protein having activity of inducing cellular apoptosis. Examples include, but are not limited to, I ⁇ B, Smac/DIABLO, ICE, HtrA2/OMI, AIF, endonuclease G, Bax, Bak, Noxa, Hrk (harakiri), Mtd, Bim, Bad, Bid, PUMA, activated caspase-3, Fas, and Tk.
- Bim is preferably used as the apoptosis-inducing gene.
- a suicide gene is a gene, the cellular expression of which is lethal to the cell.
- the suicide gene product e.g., diphtheria toxin A
- the suicide gene product by itself, may cause cell death.
- expression of such a gene may make cells susceptible to a specific chemical (e.g., expression of herpes simplex virus thymidine kinase gene can make cells susceptible to an anti-virus compound).
- the suicide gene examples include, but are not limited to, genes encoding: diphtheria toxin A; herpes simplex virus thymidine kinase (HSV-TK); carboxypeptidase G2 (CPG2); carboxyl esterase (CA); cytosine deaminase (CD); cytochrome P450 (cyt-450); deoxycytidine kinase (dCK); nitroreductase (NR); purine-nucleoside phosphorylase (PNP); thymidine phosphorylase (TP); varicella-zoster virus thymidine kinase (VZV-TK); and xanthine-guanine phosphoribosyl transferase (XGPRT).
- HSV-TK gene is preferably used as the suicide gene.
- the marker gene may include a gene encoding a localization signal.
- the localization signal include a nuclear localization signal, a plasma membrane localization signal, a mitochondrial localization signal, and a protein secretion signal. Specific examples include, but are not limited to, a classical nuclear localization signal (NLS), M9 sequence, a mitochondrial target sequence (MTS), and an ER localization sequence.
- NLS classical nuclear localization signal
- M9 M9 sequence
- MTS mitochondrial target sequence
- ER localization sequence an ER localization sequence.
- a nucleic acid sequence specifically recognized by an miRNA is operably linked to a nucleic acid sequence corresponding to a coding region of a first marker gene” means that at least one miRNA target sequence is included in a 5′ UTR, a 3′ UTR of an open reading frame (including a start codon) encoding a marker gene and/or the open reading frame.
- An miRNA-responsive mRNA includes, preferably from the 5′ end, in the 5′ to 3′ direction, a cap structure (7-methylguanosine 5′-phosphate), and an open reading frame encoding a marker gene, and a poly-A tail, and also includes at least one miRNA target sequence in a 5′ UTR, a 3′ UTR, and/or the open reading frame.
- the position of the miRNA target sequence of the mRNA may be located at the 5′ UTR or 3′ UTR or located within the open reading frame (on the 3′ side of the start codon), all of which may each be provided with an miRNA target sequence.
- the number of the miRNA target sequences may be 1, 2, 3, 4, 5, 6, 7, 8, or more.
- the nucleic acid sequences (i) and (ii) of the miRNA-responsive mRNA are linked from the 5′ to 3′ direction in this order.
- the number and kinds of bases between the cap structure and the miRNA target sequence may be freely chosen as long as the bases involve neither a stem structure nor a specific conformation.
- the number of bases between the cap structure and the miRNA target sequence is from 0 to 50 and preferably from 10 to 30.
- the number and kinds of bases between the miRNA target sequence and the start codon may be freely chosen as long as the bases involve neither a stem structure nor a specific conformation.
- the number of bases between the miRNA target sequence and the start codon is from 0 to 50 and preferably from 10 to 30.
- the miRNA target sequence of an miRNA-responsive mRNA preferably includes no AUG, a start codon.
- the AUG is in the same frame of a marker gene linked on the 3′ side.
- the AUG in the target sequence may be changed to GUG.
- the position of the target sequence in the 5′ UTR may be changed appropriately. For instance, in some position designs, the number of bases between the cap structure and the AUG sequence in the target sequence is from 0 to 60 such as from 0 to 15, from 10 to 20, from 20 to 30, from 30 to 40, from 40 to 50, and from 50 to 60.
- an miRNA target sequence is present in a 5′ UTR in the present invention
- the following sequences for example, may be used.
- the following sequence may be used downstream (i.e., in a 3′ UTR) of a subsequent marker gene.
- any one of the above-described genes may be used as the marker gene interposed between the 5′ UTR and the 3′ UTR.
- UTR sequence 3′ UTR sequence SEQ ID NO: CCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGGCC 1 3 UUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUG GAAGGCAGAAACGACAUGGCCCUGAAGCUCGUGGGC GGGAGCCAUCUGAUCGCAAACAUCAAGACCACAUAU AGAUCCAAGAAACCCGCUAAGAACCUCAAGAUGCCU GGCGUCUACUAUGUGGACUACAGACUGGAAAGAAUC AAGGAGGCCAACAACGAGACCUACGUCGAGCAGCAC GAGGUGGCAGUGGCCAGAUACUGCGACCUCCCUAGC AAACUGGGGCACAGAUCUCAUAUGCAUCUCGAGUGA UAGUCUAGACCUUCUGCGGCUUGCACCUGUACCUCUUGG UCUUUGAAUAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- a gene encoding BFP for example, is used as a marker gene in the present invention
- the following sequences may each be employed as a full-length miRNA-responsive mRNA according to the present invention.
- miRNAs and the full-length sequences of corresponding miRNA-responsive mRNAs Name of miRNA- responsive mRNA Full-lenghth miRNA-responsive mRNA SEQ ID NO: miR-126-3P GGUUCCUUAAUCGCGGAUCCCGCAUUAUUACUCACGGUACG 1 4 AAGAUCACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAU UAAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCG UGGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGC AAGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGU CGAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUA CUAGCUUCCUACGGCAGCAAGACCUUCAUCAACCACACC CAGGGCAUCCCCGACUUCUUCCCUGAGGG CUUCACAUGGGAGGG CUUCACAUGCC CAGGGCAUCCCCGACUUCUUCCCUGAGGG CUUCACAUGGGAGGG
- an miRNA-responsive mRNA can be introduced as a form of DNA or mRNA.
- examples of a technique used to introduce the DNA into a somatic cell include use of vectors (e.g., a virus, a plasmid, an artificial chromosome), lipofection, liposome, and microinjection.
- virus vector include a retrovirus vector, a lentivirus vector (e.g., Cell, 126, pp. 663-676, 2006; Cell, 131, pp. 861-872, 2007; Science, 318, pp. 1917-1920, 2007), an adenovirus vector (Science, 322, 945-949, 2008), an adeno-associated virus vector, and a sendaivirus vector (WO 2010/008054).
- the artificial chromosome vector examples include a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), and a bacterial artificial chromosome (BAC, PAC).
- HAC human artificial chromosome
- YAC yeast artificial chromosome
- BAC bacterial artificial chromosome
- plasmid plasmids for mammalian cells may be used (Science, 322:949-953, 2008).
- the vector may contain control sequences such as a promoter, an enhancer, a ribosome binding sequence, a terminator, and a polyadenylation site.
- the vector may further contain: a drug resistance gene (e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene); a selection marker sequence (e.g., a thymidine kinase gene, a diphtheria toxin gene); and/or a reporter gene sequence (e.g., genes encoding green fluorescent protein (GFP), ⁇ -glucuronidase (GUS), FLAG).
- a drug resistance gene e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene
- a selection marker sequence e.g., a thymidine kinase gene, a diphtheria toxin gene
- a reporter gene sequence e.g., genes encoding green fluorescent protein (GFP), ⁇ -glucuronidase (GUS), FLAG.
- RNA-responsive mRNA is the form of RNA
- examples of a technique for introducing the mRNA into a somatic cell include lipofection and microinjection.
- 5-methylcytidine and/or pseudouridine may be incorporated into the RNA to be used (Warren L, (2010) Cell Stem Cell. 7: 618-630).
- modified bases all or some of uridines or cytidines may be replaced by the modified base independently. When some of them are replaced, the percentage of the modified base may be freely chosen and the position or positions may be at random.
- Two or more different miRNA-responsive mRNAs may be introduced.
- an miRNA-responsive mRNA and an mRNA as a control hereinafter, sometimes referred to as a control mRNA
- multiple mRNAs are preferably co-introduced.
- the ratio between two or more co-introduced mRNAs can be maintained in individual cells. So, the activity ratio between proteins expressed using these mRNAs can be also maintained in a corresponding cell population.
- the amount of each mRNA introduced varies depending on a cell population into which the mRNAs are introduced, the mRNAs introduced, and a method and reagent for the introduction, and may be suitably selected by those skilled in the art so as to achieve a desired level of translation thereof.
- a control mRNA for example, consists of a sequence comprising a nucleic acid corresponding to a coding region of a marker gene or a sequence comprising a nucleic acid corresponding to a coding region of a drug resistance gene, and does not have an miRNA target site.
- the control mRNA together with an miRNA-responsive mRNA is introduced into a cell population. Then, the control mRNA can function as a control for identifying and distinguishing a cell containing the miRNA-responsive mRNA from others.
- control mRNA can also function as a control used when a level of signal (e.g., fluorescence and light) from the miRNA-responsive mRNA is quantified.
- a level of signal e.g., fluorescence and light
- the amount of the control mRNA introduced may be suitably selected by those skilled in the art so as to achieve a desired level of translation thereof.
- drug resistance gene it is possible to use any gene that can express a protein resistant to a corresponding drug.
- examples include, but are not limited to, antibiotic resistance genes.
- the antibiotic resistance gene include a kanamycin resistance gene, an ampicillin resistance gene, a puromycin resistance gene, a blasticidin resistance gene, a gentamicin resistance gene, a kanamycin resistance gene, a tetracycline resistance gene, and a chloramphenicol resistance gene.
- a puromycin resistance gene or a blasticidin resistance gene is preferably used as the antibiotic resistance gene.
- a sorting method more preferably includes a step of simultaneously introducing an miRNA-responsive mRNA and a control mRNA into a cell population containing a target cell.
- the step may be preferably performed by co-transfecting the miRNA-responsive mRNA and the control mRNA.
- Use of the control mRNA allows for sorting of, as a target cell, a cell in which a marker protein is less or hardly translated from the miRNA-responsive mRNA even if the efficiency of introducing the miRNA-responsive mRNA into cells is low.
- a marker gene included in the control mRNA is preferably different from a marker gene included in an miRNA-responsive mRNA.
- the marker gene included in an miRNA-responsive mRNA is an apoptosis-inducing gene or a suicide gene
- the marker gene included in the control mRNA may be a fluorescent protein-encoding gene.
- fluorescent cells are subjected to, for example, FACS sorting for selective separation. Then, cells with reduced levels of expression of the apoptosis-inducing gene or the suicide gene are sorted as target cells. This can improve sorting precision.
- a control mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of a drug resistance gene can be used with an miRNA-responsive mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of any marker gene.
- miRNA-responsive mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of any marker gene.
- cells containing the miRNA-responsive mRNA are resistant to the drug regardless of the kind of the marker gene, which can improve sorting precision.
- the same type of gene may be used for marker genes included in an miRNA-responsive mRNA and a control mRNA.
- fluorescent protein-encoding genes may be used for the marker genes included in an miRNA-responsive mRNA and a control mRNA. In this case, two corresponding fluorescent proteins should have different fluorescence wavelengths.
- the fluorescent protein-encoding gene may be replaced by a gene encoding a light-emitting protein or a protein that helps emit fluorescence, light, or color, which gene is likewise used in combination.
- control mRNA examples include, but are not particularly limited to, the following mRNAs.
- a sorting method may comprise a step of introducing an miRNA-responsive mRNA and an optional control mRNA into a cell population.
- This step allows a target type of cell to be sortable from the cell population containing the target type of cell.
- this step enables a desired type of cell to provide detectable signal information different from signal information of the other types of cell in the cell population containing two or more types of cell optionally including the target type of cell.
- the sorting step may further be carried out to selectively separate the target type of cell.
- endothelial cells are squamous thin cells constituting the inner surface of a blood vessel and are not distinguished from endothelial precursor cells in the present invention.
- Endothelial cells used in the present invention may be continuously cultured to form a tubular structure.
- the cells can take up acetylated low-density-lipoproteins (ac-LDL).
- ac-LDL acetylated low-density-lipoproteins
- the endothelial cells are characterized by expression of a marker including, without particular limitation, CD31, etc.
- a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting an endothelial cell is preferably a nucleic acid sequence specifically recognized by miR-126-3P or miR-126-5P.
- a cell population that is subject to sorting may contain any cell population that can contain endothelial cells.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto.
- an miRNA-responsive mRNA is introduced into a cell population that may or may not contain endothelial cells.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell.
- Such induced differentiation is not limited to specific induction into endothelial cells, and may include induced differentiation for the purpose of obtaining another type of cell such as cardiomyocytes.
- a protocol for producing endothelial cells from a pluripotent stem cell may be appropriately performed, including, for example, the known procedure (Li et al., J. Cell Biochem., 106: 194-199, 2009).
- hepatocytes are defined as cells expressing an mRNA of albumin or HNF4A. According to another embodiment of the present invention, hepatocytes are defined as cells characterized by any one or combination of known hepatocyte functions such as glycogen accumulation, low-density-lipoprotein (LDL) incorporation, albumin secretion, ammonia metabolism and urea synthesis, cytochrome P450 activity, lipid metabolism, and drug metabolism.
- LDL low-density-lipoprotein
- a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting a hepatocyte is preferably a nucleic acid sequence specifically recognized by miR-122-5P.
- a cell population that is subject to sorting may contain any cell population that can contain hepatocytes.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto.
- an miRNA-responsive mRNA is introduced into a cell population that may or may not contain hepatocytes.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell. Such induced differentiation is not limited to specific induction into hepatocytes.
- a protocol for producing hepatocytes from a pluripotent stem cell may be appropriately performed, including the known procedures (e.g., WO2001/081549; Takayama K, et al., Stem Cell Reports. 1: 322-335, 2013; Kajiwara M, et al., Proc Natl Acad Sci USA. 109: 12538-12543, 2012; Hay D C, et al., Stem Cells. 26: 894-902, 2008).
- insulin-producing cells are defined as cells expressing an mRNA of insulin.
- a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting an insulin-producing cell is preferably a nucleic acid sequence specifically recognized by miR-375.
- a cell population that is subject to sorting may contain any cell population that can contain insulin-producing cells.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto.
- an miRNA-responsive mRNA it may be possible for an miRNA-responsive mRNA to be introduced into a cell population that may or may not contain insulin-producing cells.
- the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell. Such induced differentiation is not limited to specific induction into insulin-producing cells.
- Examples of a protocol for inducing insulin-producing cells from a pluripotent stem cell include methods for induced differentiation using activin and/or retinoic acid (RA) (Japanese Patent Laid-Open No. 2009-225661, E. Kroon et al., Nature Biotechnology (2008) Vol. 26, No. 4: 443-452, K. A. D'Amour et al., Nature Biotechnology (2006) Vol. 24, No. 11: 1392-1401, W. Jiang, Cell Research (2007) 17: 333-344, J. H. Shim et al., Diabetologia (2007) 50: 1228-1238, R. Maehra et al., PNAS (2009), vol. 106, No. 37: 15768-15773).
- RA retinoic acid
- Additional examples include: methods including introducing PDX1 into a pluripotent stem cell and culturing the cell (U.S. Pat. No. 7,534,608 and Japanese Patent Laid-Open No. 2006-075022); and methods for producing insulin-producing cells by applying a suitable combination of low-molecular-weight compounds to a pluripotent stem cell (WO2011/081222 and Kunisada Y et al., Stem Cell Res. (2012) vol. 8, No. 2: 274-284).
- a pluripotent stem cell is a stem cell that is pluripotent and can differentiate into many types of cells in vivo and can also self-replicate, and includes any type of cell that can be induced into hepatocytes used in the present invention.
- the pluripotent stem cell include, but are not particularly limited to, an embryonic stem (ES) cell, a nuclear transfer-mediated clone embryo-derived embryonic stem (ntES) cell, a germline stem cell (“GS cell”), an embryonic germ cell (“EG cell”), an induced pluripotent stem (iPS) cell, and a fibroblast or bone marrow stem cell-derived pluripotent cell (Muse cell).
- ES embryonic stem
- ntES nuclear transfer-mediated clone embryo-derived embryonic stem
- GS cell germline stem cell
- EG cell embryonic germ cell
- iPS induced pluripotent stem
- Muse cell fibroblast or bone marrow stem cell-derived pluripotent cell
- An embryonic stem cell is a stem cell that has been established from an inner cell mass of an early embryo (e.g., a blastocyst) of a mammal such as a human and a mouse and that is pluripotent and can self-replicate.
- the ES cell is an embryonic stem cell derived from an inner cell mass of a blastocyst, an embryo after an 8-cell stage and morula of a fertilized egg, and has an ability to differentiate into all the cells constituting an adult body, what is called pluripotency, and can self-replicate.
- the ES cell was discovered in a mouse in 1981 (M. J. Evans and M. H. Kaufman (1981), Nature 292: 154-156). Later, ES cell lines were established in primates such as a human and a monkey (J. A. Thomson et al. (1998), Science 282: 1145-1147; J. A. Thomson et al. (1995), Proc. Natl. Acad. Sci.
- An ES cell can be established by isolating an inner cell mass from a blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder layer.
- the cells can be maintained by splitting the culture using a culture medium containing, for example, leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF).
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- Human and monkey ES cells have been established and maintained in accordance with the procedures described in, for example, U.S. Pat. No. 5,843,780; Thomson J A, et al. (1995), Proc Natl. Acad. Sci. USA. 92: 7844-7848; Thomson J A, et al. (1998), Science. 282: 1145-1147; H.
- a culture medium for producing an ES cell it is possible to use DMEM/F-12 culture medium supplemented with, for example, 0.1 mM 2-mercaptoethanol, 0.1 mM non-essential amino acids, 2 mM L-glutamine, 20% KSR, and 4 ng/ml bFGF. Then, the human ES cell can be maintained at 37° C. and 5% CO 2 under a humid atmosphere (H. Suemori et al. (2006), Biochem. Biophys. Res. Commun., 345: 926-932). In addition, the ES cells should be divided every 3 to 4 days. At this time, the cells may be divided using, for example, 0.25% trypsin and 0.1 mg/ml collagenase IV in PBS containing 1 mM CaCl 2 and 20% KSR.
- the ES cells can be selected, in general, by a real-time PCR method using, as an indicator, expression of gene markers such as alkaline phosphatase, Oct-3/4, and Nanog genes.
- human ES cells can be selected by using, as an indicator, expression of gene markers such as OCT-3/4, NANOG, and ECAD genes (E. Kroon et al. (2008), Nat. Biotechnol., 26: 443-452).
- WA01 (H1) and WA09 (H9) are available from WiCell Research Institute and KhES-1, KhES-2, and KhES-3 are available from the Institute for Frontier Medical Sciences, Kyoto University (Kyoto, Japan).
- the germline stem cell is a testis-derived pluripotent stem cell, which is a source of spermatogenesis.
- This cell like the ES cell, can be induced to differentiate into various cell lineages, characterized in that when this cell is transplanted in a mouse blastocyst, for example, a chimeric mouse can be generated (M. Kanatsu-Shinohara et al. (2003) Biol. Reprod., 69:612-616; K. Shinohara et al. (2004), Cell, 119: 1001-1012).
- This cell can self-replicate in a culture medium containing glial cell line-derived neurotrophic factor (GDNF).
- GDNF glial cell line-derived neurotrophic factor
- a germline stem cell can be obtained (Masanori Takebayashi et al. (2008), “ Jikken Igaku (Experimental Medicine)”, vol. 26, no. 5 (special issue), pages 41-46, YODOSHA CO., LTD. (Tokyo, Japan)).
- the embryonic germ cell has been established from an embryonic primordial germ cell and, like an ES cell, is pluripotent. Also, an embryonic germ cell can be established by culturing a primordial germ cell in the presence of substances such as LIF, bFGF, and stem cell factor (Y. Matsui et al. (1992), Cell, 70: 841-847; J. L. Resnick et al. (1992), Nature, 359: 550-551).
- An induced pluripotent stem (iPS) cell can be created by introducing, as a form of DNA, RNA, or protein, specific reprogramming factors into a somatic cell, and is a somatic cell-derived induced stem cell that has substantially the same properties as of an ES cell, namely a cell having pluripotency and ability to self-replicate (K. Takahashi and S. Yamanaka (2006) Cell, 126: 663-676; K. Takahashi et al. (2007), Cell, 131: 861-872; J. Yu et al. (2007), Science, 318: 1917-1920; Nakagawa, M. et al., Nat. Biotechnol.
- iPS induced pluripotent stem
- the reprogramming factors may be composed of genes that are specifically expressed in an ES cell, the products or non-coding RNAs thereof, genes that play a critical role in keeping an ES cell undifferentiated, the products or non-cording RNAs thereof, and/or low-molecular-weight compounds.
- genes included in the reprogramming factors include Oct3/4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 and Glis 1. These reprogramming factors may be used alone or in combination.
- HDAC histone deacetylase
- VPA valproic acid
- trichostatin A sodium butyrate
- MC 1293, M344 nucleic acid expression inhibitors
- siRNAs and shRNAs against HDAC e.g., HDAC1 siRNA Smartpool (a registered trademark) (Millipore), HuSH 29mershRNA Constructs against HDAC1 (OriGene)
- MEK inhibitors e.g., PD184352, PD98059, U0126, SL327, and PD0325901
- glycogen synthase kinase-3 inhibitors e.g., Bio and CHIR99021
- DNA methyltransferase inhibitors e.g., 5-azacytidine
- histone methyltransferase inhibitors e.g., low
- the reprogramming factors may be introduced into a somatic cell by using technology such as lipofection, fusion to a cell penetrating peptide (e.g., HIV-derived TAT and polyarginine), and microinjection in the form of protein.
- a cell penetrating peptide e.g., HIV-derived TAT and polyarginine
- examples of a technique used to introduce the reprogramming factors into a somatic cell include use of vectors (e.g., a virus, a plasmid, an artificial chromosome), lipofection, liposome, and microinjection.
- virus vector include a retrovirus vector, a lentivirus vector (e.g., Cell, 126, pp. 663-676, 2006; Cell, 131, pp. 861-872, 2007; Science, 318, pp. 1917-1920, 2007), an adenovirus vector (Science, 322, 945-949, 2008), an adeno-associated virus vector, and a sendaivirus vector (WO 2010/008054).
- the artificial chromosome vector examples include a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), and a bacterial artificial chromosome (BAC, PAC).
- HAC human artificial chromosome
- YAC yeast artificial chromosome
- BAC bacterial artificial chromosome
- plasmid plasmids for mammalian cells may be used (Science, 322:949-953, 2008).
- the vector may contain a promoter, an enhancer, a ribosome binding sequence, a terminator, a poly-A site.
- the vector may further contain: a drug resistance gene (e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene); a selection marker sequence (e.g., a thymidine kinase gene, a diphtheria toxin gene); and/or a reporter gene sequence (e.g., genes encoding green fluorescent protein, ⁇ -glucuronidase (GUS), FLAG).
- a drug resistance gene e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene
- a selection marker sequence e.g., a thymidine kinase gene, a diphtheria toxin gene
- a reporter gene sequence e.g., genes encoding green fluorescent protein, ⁇ -glucuronidase (GUS), FLAG.
- the vector may contain LoxP motifs before and after the sequence.
- RNA form In the case of an RNA form, a technique such as lipofection and microinjection may be used to introduce the reprogramming factors into a somatic cell. To reduce their degradation, RNA containing 5-methylcytidine and pseudouridine (TriLink Biotechnologies) may be used (Warren L, (2010) Cell Stem Cell. 7: 618-630).
- TriLink Biotechnologies TriLink Biotechnologies
- Examples of a culture medium for iPS cell induction include: 10 to 15% FBS-containing DMEM and DMEM/F12 or DME culture medium (these culture media optionally further containing LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, ⁇ -mercaptoethanol, etc.); and commercially available culture media [e.g., mouse ES cell culture medium (TX-WES culture medium; Thromb-X N.V.), primate ES cell culture medium (primate ES/iPS cell culture medium; ReproCELL Inc.), serum-free media (mTeSR, Stemcell Technology, Inc.; Essential 8, Life Technologies, Inc.; StemFit, Ajinomoto, Inc.)].
- FBS-containing DMEM and DMEM/F12 or DME culture medium these culture media optionally further containing LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, ⁇ -mercapto
- a culture protocol includes: causing reprogramming factors to contact somatic cells in 10% FBS-containing DMEM or DMEM/F12 culture medium at 37° C. in the presence of 5% CO 2 and culturing the cells for about 4 to 7 days, and thereafter; plating the cells on a feeder cell (e.g., mitomycin C-treated STO cell, SNL cell, etc.) layer; and culturing, from about 10 days after the contact between the somatic cells and the reprogramming factors, the resulting cells in bFGF-containing primate ES cell culture medium, so that iPS-like colonies can be generated at about 30 to about 45 days or later after the contact.
- a feeder cell e.g., mitomycin C-treated STO cell, SNL cell, etc.
- the relevant cells are cultured on a feeder cell (e.g., mitomycin C-treated STO cell, SNL cell, etc.) layer in 10% FBS-containing DMEM culture medium (further optionally containing LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, ⁇ -mercaptoethanol, etc.) at 37° C. in the presence of 5% CO 2 , so that ES-like colonies can be generated after about 25 to about 30 days or later.
- somatic cells that are subject to reprogramming are used (Takahashi K, et al. (2009), PLoS One.
- WO2010/137746 e8067 or WO2010/137746
- extracellular matrix e.g., Laminin-5 (WO2009/123349), Matrigel (BD, Inc.), or iMatrix511 (Nippi, Inc.)
- Laminin-5 WO2009/123349
- Matrigel BD, Inc.
- iMatrix511 Nippi, Inc.
- an iPS cell may be established in a low oxygen condition (i.e., the level of oxygen of from 0.1% or more to 15% or less) (Yoshida Y, et al. (2009), Cell Stem Cell. 5: 237-241 or WO2010/013845)
- the culture medium is changed to a fresh medium once a day from day 2 after initiation of the culture.
- the number of somatic cells used for nuclear reprogramming has no limitation and ranges from about 5 ⁇ 10 3 to about 5 ⁇ 10 6 cells per 100 cm 2 culture dish.
- the iPS cell can be selected in accordance with the morphology of a colony formed.
- the iPS cell can be selected using, as indicators, genes (e.g., SSEA-1, SSEA-3, SSEA-4, TRA-2-54, TRA-1-60, and TRA-1-80) that are expressed when somatic cells are reprogrammed.
- genes e.g., SSEA-1, SSEA-3, SSEA-4, TRA-2-54, TRA-1-60, and TRA-1-80
- the term “somatic cell” refers to any animal cell (preferably, mammalian cells, including human cells) excluding reproductive cells (e.g., an egg cell, an oocyte, an ES cell) or totipotent cells.
- reproductive cells e.g., an egg cell, an oocyte, an ES cell
- totipotent cells e.g., an egg cell, an oocyte, an ES cell
- somatic cell include, without limitation, any of fetal somatic cells, neonatal somatic cells, and mature, healthy or disease somatic cells. Additional examples include any of primary culture cells, subcultured cells, and cell lines.
- tissue stem cells such as a neural stem cell, a hematopoietic stem cell, a mesenchymal stem cell, a dental pulp stem cell
- tissue precursor cells such as a lymphocyte, an epithelial cell, an endothelial cell, a myocyte, a fibroblast (e.g., a skin cell, etc.), a hair cell, a hepatocyte, a gastric mucosa cell, an intestinal cell, a splenocyte, a pancreatic cell (e.g., a pancreatic exocrine cell, etc.), a brain cell, a pneumocyte, a nephrocyte, and an adipocyte.
- tissue stem cells such as a neural stem cell, a hematopoietic stem cell, a mesenchymal stem cell, a dental pulp stem cell
- tissue precursor cells such as a lymphocyte, an epithelial cell, an endothelial cell, a myocyte, a
- somatic cells when used as a transplantable cell material, it is desirable from the viewpoint of there being no occurrence of rejection to use somatic cells having the same or substantially the same HLA genotype as of an individual that is subject to transplantation.
- the term “substantially the same” means that the HLA genotype is matched to such an extent that the immune reaction against the transplanted cells can be suppressed by an immunosuppressive agent.
- the somatic cells have an HLA genotype in which three gene loci: HLA-A, HLA-B, and HLA-DR are identical or four gene loci including an additional HLA-C are identical.
- a nuclear transfer-mediated clone embryo-derived ES cell is an ES cell that is derived from a clone embryo generated using a nuclear transfer technique and has substantially the same properties as of a fertilized egg-derived ES cell (T. Wakayama et al. (2001), Science, 292:740-743; S. Wakayama et al. (2005), Biol. Reprod., 72:932-936; J. Byrne et al. (2007), Nature, 450:497-502).
- the nt ES (nuclear transfer ES) cell is an ES cell that has been established from an inner cell mass of a blastocyst of a clone embryo as obtained by switching the nucleus of an unfertilized egg to the nucleus of a somatic cell.
- a nuclear transfer technique J. B. Cibelli et al. (1998), Nature Biotechnol., 16:642-646) and ES cell creation technology are combined (Sayaka Wakayama (2008), “ Jikken Igaku (Experimental Medicine)”, vol. 26, no. 5 (special issue), pages 47-52).
- the nucleus of a somatic cell is injected into an enucleated unfertilized egg of a mammal and the resulting egg is cultured for reprogramming for several hours.
- the multilineage-differentiating stress enduring cell is a pluripotent stem cell as generated by the protocol described in WO2011/007900. Specifically, fibroblasts or bone marrow stromal cells are treated with trypsin for an extended period and, preferably, the cells are treated for 8 or 16 h; and the cells are then subjected to suspension culture to yield pluripotent cells that are positive for SSEA-3 and CD105.
- Cells sorted by the present invention may be administered pharmaceutically.
- a therapeutic agent containing cells sorted by a method of the present invention When the cells sorted are endothelial cells, the cells may be administered for treatment of patients with severe ischemia including coronary artery disease and lower limb ischemia (e.g., Buerger disease, arteriosclerosis obliterans, etc.).
- an embodiment of the present invention provides a vascular regeneration promoter containing endothelial cells sorted by the above-described method.
- the cells sorted are hepatocytes
- the cells may be administered for treatment of liver failure such as chronic liver failure (e.g., hepatic cirrhosis) and acute liver failure.
- an embodiment of the present invention provides a liver disease drug containing hepatocytes obtained by the above-described method.
- the cells sorted are insulin-producing cells
- the cells may be administered for treatment of diabetes mellitus, in particular, type 1 diabetes.
- an embodiment of the present invention provides a diabetes drug containing insulin-producing cells obtained by the above-described method.
- the number of cells administered has no particular limitation as long as the dose can exert an advantageous effect on treatment.
- the cells may be prepared by appropriately adjusting the number depending on the size of a lesion and/or the body size.
- a fragment was amplified by PCR method using pTagBFP-Tubulin (evrogen) as a template and TagBFP_Tfwd and TagBFP_Trev as primers.
- the resulting fragment was inserted into pGEM-TAP, a cloning vector originally constructed by the inventors.
- the pGEM-TAP was constructed by PCR mutagenesis using pGEM-Teasy (Promega) as a template and pGEMTAP_MCS_Rev and pGEMTAP_MCS_Fwd as primers.
- a fragment was amplified by PCR method using pEGFP-N1 (Clontech) as a template and YF128_EXFP_Tfwd and YF129_EXFP_Trev as primers.
- the resulting fragment was inserted into pCM-TAP, a cloning vector originally constructed by the inventors.
- the pCM-TAP was constructed by ligating a DraI-digested fragment of the above pGEM-TAP and a blunt-ended fragment of a NheI and AgeI-digested pLysSRARE2 (Novagen).
- a fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the pTAP-tagBFP as a template, and tagBFP fwd and TAP_IVTrev as primers in a solution of Table 8 as prepared in accordance with manufacturer's instructions.
- the amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions (to yield what is called a tagBFP PCR product).
- DpnI TOYOBO
- QIAGEN MiniElute PCR purification kit
- a fragment was amplified by PCR using the pCTp-EGFP as a template and TAPEGFP_IVTfwd and TAP_IVTrev as primers.
- the PCR amplification was carried out and the resulting PCR product (called an EGFP PCR product) was purified.
- a fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the IVT_5prime_UTR, which is shown in Table 10, as a template, and TAP_T7_G3C fwd primer and Rev5UTR primer as primers in a solution of Table 9 as prepared in accordance with manufacturer's instructions.
- the amplified PCR product was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions (to yield what is called a 5′UTR PCR product).
- QIAGEN MiniElute PCR purification kit
- a fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the above-described EGFP PCR product, 5′ UTR PCR product and 3′ UTR PCR product as templates, and TAP_T7_G3C fwd primer and 3UTR120A rev primer as primers in a solution of Table 11 as prepared in accordance with manufacturer's instructions.
- the amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions.
- the IVT template for an miRNA switch was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the above-described tagBFP PCR product, each miRNA target 5′UTR oligo-DNA, and the above-described 3′ UTR PCR product as templates, and T7FwdB primer and 3UTR120A rev primer as primers in a solution of Table 12 as prepared in accordance with manufacturer's instructions.
- Table 13 lists each miRNA target 5′ UTR oligo-DNA.
- the amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions.
- Each mRNA was produced using a MEGAscript T7 kit (Ambion) and each IVT template in accordance with the protocol described in Warren L, et al., Cell Stem Cell. 7(5): 618-30 (2010).
- pseudouridine-5′-triphosphate and methylcytidine-5′-triphosphate (TriLink BioTechnologies) were used as alternatives for uridine triphosphate and cytidine triphosphate, respectively.
- guanidine-5′-triphosphate was diluted five-fold with Anti-Reverse Cap Analog (New England Biolabs). The reaction mixture was incubated at 37° C.
- TURBO DNase (Ambion) was added, and the resulting mixture was then further incubated at 37° C. for 30 min.
- the resulting mRNA was purified through FavorPrep Blood/Cultured Cells total RNA extraction column (Favorgen Biotech), and was incubated with Antarctic phosphatase (New England Biolabs) at 37C° for 30 min. After that, the mRNA was further purified using an RNeasy Mini Elute Cleanup kit (QIAGEN).
- Human umbilical vein endothelial cells (HUVECs) (C2517A) were purchased from Lonza, Inc., and were cultured using an EGM-2 Endothelial Cell Growth Medium-2 Bullet kit (Lonza).
- the miRNA expression was profiled using Agilent Technologies Human miRNA Microarray Release 19.0 in accordance with the manufacturer's protocol. The data was analyzed using GeneSpring GX 12.6 software (Agilent Technologies).
- human iPS cells used was 201B7 cell line described in Takahashi K, et al. Cell. 131: 861-72, 2007, 409B2 (available from Riken BioResource Center), or 606A1 described in Okita K, et al., Stem Cells 31, 458-66, 2012.
- KhES1 was used and obtained from Kyoto University.
- the human iPS cells or ES cells were treated with CTK solution (ReproCELL) for 2 min. Next, the solution was removed. Subsequently, the cells were treated with Accumax (Innovative Cell Technologies) for 5 min. Then, the cells were subjected to pipetting to single cells.
- the resulting cells were recovered by centrifugation, transferred to a low-attachment 6-well dish (Corning), and cultured at 37° C. under 5% oxygen condition in 1.5 ml/well of STEMPRO 34 (Invitrogen) supplemented with 2 mM L-glutamine, 150 ⁇ g/mL transferrin, 50 ⁇ g/mL ascorbic acid (sigma), 4 ⁇ 10 ⁇ 4 M monothioglycerol (MTG), 0.5% penicillin/streptomycin (Invitrogen), 10 ⁇ M ROCK inhibitor (Y-27632), and 2 ng/mL BMP4 (R&D) to induce EB formation (day 0).
- STEMPRO 34 Invitrogen
- IMDM Invitrogen
- STEMPRO 34 supplemented with 2 mM L-glutamine, 150 ⁇ g/mL transferrin, 50 ⁇ g/mL ascorbic acid, 4 ⁇ 10 ⁇ 4 M MTG, 10 ng/mL VEGF, and 1 ⁇ M IWP-3 (Stemgent).
- the resulting culture was cultured at 37° C. under 5% oxygen condition for 4 days.
- the medium was changed to STEMPRO 34 supplemented with 2 mM L-glutamine, 150 ⁇ g/mL transferrin, 50 ⁇ g/mL ascorbic acid, 4 ⁇ 10 ⁇ 4 M MTG, 0.5% penicillin/streptomycin, 10 ng/mL VEGF, and 5 ng/mL bFGF.
- the resulting culture was cultured at 37° C. under 5% oxygen condition for 4 days.
- the medium change under the same conditions was performed once every two days.
- Twelve days after the induction (day 12) the culture was transferred to an incubator with a normal oxygen level and was further cultured for 8 days. At this occasion, the medium change under the same conditions was performed once every two days.
- the endothelial cells isolated were seeded at 2 ⁇ 10 5 cells/well on a Matrigel (BD)-coated 24-well plate, and were cultured in EGM-2 Bullet Kit medium. Next day, the culture was observed under a Biorevo BZ-9000 microscope.
- BD Matrigel
- hsa-miR-10b-5p, hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-196b-5p, and hsa-miR-216a-5p were used for microarray analysis; and top 5 miRNAs (hsa-miR-10b-5p, hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-196b-5p, and hsa-miR-216a-5p) specifically expressed in the endothelial cells were discovered ( FIG. 1A ).
- miRNA switches each having BFP and a sequence specifically recognized by each miRNA, (hereinafter, each referred to as miR-** miRNA switch) were constructed by the procedure described in Example 1 and each miRNA switch together with EGFP mRNA as a control was introduced into HUVECs.
- miR-** miRNA switch As a result, HUVECs of interest were successfully isolated using each of miR-126-3p miRNA switch and miR-126-5p miRNA switch ( FIG. 1B ).
- both BFP mRNA and EGFP mRNA were together introduced into HUVECs. This result was compared with the above result and the isolation was verified.
- the miR-126-3p miRNA switch and the miR-126-5p miRNA switch are useful in isolating endothelial cells from a heterogeneous cell population. Further, the cells that were isolated using the miR-126-5p miRNA switch were subjected to tube formation assay. The results demonstrated that the cells had angiogenic potential ( FIG. 2C ).
- Human primary hepatocytes were purchased from Bioreclamation IVT and were cultured in InVitroGRO CP Medium (Bioreclamation IVT) supplemented with Torpedo Antibiotic Mix (Bioreclamation IVT).
- human iPS cells used was 201B6 cell line described in Takahashi K, et al., Cell. 131: 861-72, 2007. Hepatocytes were induced from human iPS cells in accordance with the method, with a modification, described in Kajiwara M, et al., Proc Natl Acad Sci USA. 109: 12538-12543, 2012. Specifically, the human iPS cells were seeded on a Matrigel-coated plate. Next, to the plate was added RPMI 1640 medium supplemented with 1 ⁇ B27 supplement, 100 ng/ml activin A, 10 ⁇ M Y-27632, and 1 ⁇ M CHIR99021.
- the medium was changed to a culture medium in which Y-27632 had been removed from and 0.5 mM NaB had been added to the above medium.
- the medium was changed to knockout DMEM supplemented with 20% knockout serum replacement (KSR), 1 mM L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, 1% DMSO, 10 ng/ml FGF, and 20 ng/ml BMP4, and the cells were cultured for 6 days.
- the medium was changed to hepatocyte culture medium (Lonza) supplemented with 20 ng/ml hepatocyte growth factor (HGF) and 20 ng/ml oncostatin M (OSM). The culture mixture was further cultured for seven days to yield hepatocytes.
- HGF hepatocyte growth factor
- OSM oncostatin M
- hepatocytes To isolate hepatocytes, primary hepatocytes were used for microarray analysis; and top 5 miRNAs (hsa-miR-122-3p, hsa-miR-122-5p, hsa-miR-192-5p, hsa-miR-194-5p, and hsa-miR-215) specifically expressed in hepatocytes were discovered ( FIG. 4A ).
- Corresponding miRNA switches were constructed by the procedure of Example 1 and each miRNA switch together with EGFP mRNA as a control is introduced into hepatocytes derived from induced differentiation of human iPS cells. As a result, cells of interest were successfully isolated using miR-122-5p miRNA switch ( FIG. 4B ).
- human iPS cells used was 585A1 cell line described in Okita K, et al., Stem Cells 31, 458-66, 2012. Insulin-producing cells were induced from human iPS cells in accordance with the process described in Kunisada Y, et al., Stem Cell Res. 8:274-284, 2012 and Nakagawa, M, et al., Sci Rep 4, 3594, 2014. Specifically, the cells were cultured for 1 day in RPMI 1640 medium supplemented with 1 ⁇ B27 supplement, 10 ⁇ M Y-27632, and 3 ⁇ M CHIR99021.
- the medium was changed to RPMI 1640 medium containing 1 ⁇ B27 supplement, 100 ng/ml activin A, and 1 ⁇ M CHIR99021, and the cells were cultured for 3 days. Subsequently, the medium was changed to Improved MEM Zinc Option medium supplemented with 0.5 ⁇ B27 supplement, 1 ⁇ M dorsomorphin, 2 ⁇ M retinoic acid, and 10 ⁇ M SB431542, and the cells were cultured for 6 days.
- the medium was changed to Improved MEM Zinc Option medium supplemented with 0.5 ⁇ B27 supplement, 10 ⁇ M forskolin, 10 ⁇ M dexamethasone, 5 ⁇ M Alk5 inhibitor II, and 10 mM nicotinamide, and the cells were cultured for 8 days.
- miR-375 miRNA switch was constructed by the above procedure and the miR-375 miRNA switch together with EGFP mRNA as a control was introduced into insulin-producing cells derived from induced differentiation of human iPS cells. As a result, cells of interest were successfully isolated using the miRNA switch ( FIGS. 6A and 6B ). The cells isolated were confirmed to be positive for INSULIN by immunostaining ( FIG. 6C ).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An object of the present invention is to provide a method for increasing the purity of a type of tissue cell such as an endothelial cell, a hepatocyte, or an insulin-producing cell. The present invention solves the problem by providing a method comprising a step of introducing, into a cell population, an mRNA comprising a nucleic acid sequence recognized by an miRNA specifically expressed in endothelial cells, hepatocytes, or insulin-producing cells.
Description
- This application is a divisional of and claims priority to U.S. patent application Ser. No. 15/568,209 filed Dec. 1, 2017, which is a 35 U.S.C. § 371 national phase application of PCT Application PCT/JP2016/062710 filed Apr. 22, 2016, which claims priority to Japanese Application No. 2015-087805 filed Apr. 22, 2015. The entire contents of each are incorporated herein by reference in its entirety.
- A Sequence Listing in ASCII text format, submitted under 37 C.F.R. § 1.821, entitled 5576-341DV_ST25.txt, 14,492 bytes in size, generated on Oct. 18, 2019 and filed via EFS-Web, is provided in lieu of a paper copy. This Sequence Listing is incorporated by reference into the specification for its disclosures.
- The present invention relates to a method for sorting tissue cells, and in particular, relates to a method for sorting an endothelial cell, a hepatocyte, and an insulin-producing cell.
- Much attention has been paid to cell transplantation therapy using pluripotent stem cells, and methods for inducing each tissue cell have been reported (Kajiwara M, et al., Proc Natl Acad Sci USA. 109:12538-12543, 2012; Kunisada Y, et al., Stem Cell Res. 8:274-284, 2012; Nakagawa, M, et al., Sci Rep 4, 3594, 2014). However, all the cells induced are not just a desired type of cell and usually contain other types of cell at the same time. To use such a cell population as cells used for transplantation, it is necessary to increase the purity of a desired type of cell by sorting, etc.
- Recently, a method has been conducted in which a desired type of cell is sorted by using one or more cell surface markers. Unfortunately, a specific surface marker has not been identified with respect to every tissue cell type.
- In view of the above conventional technique, a novel sorting method from another viewpoint is desirable so as to increase the purity of a target type of tissue cell. That is, an object of the present invention is to provide a tool for sorting each type of tissue cell.
- The present inventors have conducted intensive research to solve the above problem and then have found that each miRNA-responsive mRNA can be used to allow a type of tissue cell such as an endothelial cell, a hepatocyte, or an insulin-producing cell to be purified with high purity. Specifically, miRNAs expressed specifically in each tissue cell population were identified by microarray analysis. Then, an mRNA (miRNA switch) having a marker gene and a target sequence of each of the above miRNAs was constructed. Then, this mRNA was introduced into cells that were subject to sorting. In the cell population, cells exhibiting different behavior were found to be present. When sorted, these cells were confirmed to be a target type of tissue cell with high purity. In this way, a desired tissue cell sorting method was discovered. The present invention has been completed based on such findings.
- Specifically, the present invention provides the following items.
- [1] A method for sorting an endothelial cell, comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- (i) a nucleic acid sequence recognized specifically by miR-126-3P or miR-126-5P; and
- (ii) a nucleic acid sequence corresponding to a coding region of a first marker gene.
- [2] A method for sorting a hepatocyte, comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- (i) a nucleic acid sequence recognized specifically by miR-122-5P; and
- (ii) a nucleic acid sequence corresponding to a coding region of a first marker gene.
- [3] A method for sorting an insulin-producing cell, comprising introducing an miRNA-responsive mRNA into a cell population, the miRNA-responsive mRNA comprising:
- (i) a nucleic acid sequence recognized specifically by miR-375; and
- (ii) a nucleic acid sequence corresponding to a coding region of a first marker gene.
- [4] The method according to any one of items [1] to [3], wherein the miRNA-responsive mRNA comprises a nucleic acid sequence having (i) and (ii) linked in a 5′ to 3′ direction.
- [5] The method according to any one of items [1] to [4], wherein the first marker gene of (ii) is one or more genes selected from the group consisting of a fluorescent protein-encoding gene, an apoptosis-inducing gene, and a suicide gene.
- [6] The method according to item [5], wherein the fluorescent protein-encoding gene is a blue fluorescent protein (BFP)-encoding gene.
- [7] The method according to item [5], wherein the apoptosis-inducing gene is a Bim protein-encoding gene.
- [8] The method according to any one of items [1] to [7], wherein a cell having a low level of translation of the first marker gene is sorted as the cell of interest.
- [9] The method according to any one of items [1] to [8], further comprising introducing, into the cell population, an mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of a second marker gene, wherein a cell in which the second marker gene is translated is sorted as the cell of interest, and wherein the second marker gene is a fluorescent protein-encoding gene different from the first marker gene, or a drug resistance gene.
- [10] The method according to any one of items [1] to [9], wherein the cell population is a cell population that has been induced to differentiate from a pluripotent stem cell.
- [11] A method for producing endothelial cells, comprising:
- (a) producing, from a pluripotent stem cell, a cell population containing endothelial cells;
- (b) introducing, into the cell population of the step (a), an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-126-3P or miR-126-5P and (ii) a nucleic acid corresponding to a coding region of a first marker gene; and
- (c) sorting a cell having a low level of translation of the first marker gene of the step (b).
- [12] A method for producing hepatocytes, comprising:
- (a) producing, from a pluripotent stem cell, a cell population containing hepatocytes;
- (b) introducing, into the cell population of the step (a), an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-122-5P and (ii) a nucleic acid corresponding to a coding region of a first marker gene; and
- (c) sorting a cell having a low level of translation of the first marker gene of the step (b).
- [13] A method for producing insulin-producing cells, comprising:
- (a) producing, from a pluripotent stem cell, a cell population containing insulin-producing cells;
- (b) introducing, into the cell population of the step (a), an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-375 and (ii) a nucleic acid corresponding to a coding region of a first marker gene; and
- (c) sorting a cell having a low level of translation of the first marker gene of the step (b).
- [14] The method according to any one of items [11] to [13], wherein the miRNA-responsive mRNA comprises a nucleic acid sequence having (i) and (ii) linked in a 5′ to 3′ direction.
- [15] The method according to any one of items [11] to [14], wherein the first marker gene of (ii) is one or more genes selected from the group consisting of a fluorescent protein-encoding gene, an apoptosis-inducing gene, and a suicide gene.
- [16] The method according to any one of items [11] to [15], further comprising: introducing, into the cell population, an mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of a second marker gene, wherein a cell in which the second marker gene is translated is sorted as the cell of interest, and wherein the second marker gene is a fluorescent protein-encoding gene different from the first marker gene, or a drug resistance gene.
- In accordance with the method of the present invention, tissue cells such as endothelial cells, hepatocytes, and insulin-producing cells can be easily sorted and purified to high purity. The mRNA that has been introduced into a cell population using the method according to the present invention is only transiently present in cells. Therefore, this makes it possible to sort target cells safely without the mRNA being introduced into the genome. In addition, the present invention discloses a method in which living cells can be sorted, without fixation, on the basis of the level of expression of an intracellular active miRNA. Further, cells purified in accordance with the method of the present invention can be used for transplantation therapy.
-
FIG. 1A shows the results of comparing, using a microarray, the levels of expression of miRNAs between HUVEC and smooth muscle cells (AoSMC) (left panel) or cardiomyocytes (MYH6-EIP4 d20 CMs) (right panel). The lower diagram is a Venn diagram showing the analysis results.FIG. 1B shows the flow cytometry analysis results obtained after each miRNA switch (containing miR-208, miR-10b-5p, miR-126-3p, miR-126-5p, miR-196b-5, and miR-216a5p) or BFP together with EGFP were introduced into HUVECs. -
FIG. 2A shows the flow cytometry analysis results obtained after each miRNA switch (containing miR-208, miR-10b-5p, miR-126-3p, miR-126-5p, miR-196b-5, or miR-216a5p) together with EGFP was introduced into a cardiomyocyte population containing endothelial cells derived from induced differentiation of iPS cells.FIG. 2A also shows the results obtained by gating the cells in each gate above and by staining them with an anti-CD31 antibody. The term “negative fraction” means that the results obtained by gating the cells outside the above gate and by staining them with the anti-CD31 antibody.FIG. 2B is a graph showing the percentage of CD31-positive cells in cells sorted using each miRNA switch (miR-208, miR-126-3p, and miR-126-5p) from a cardiomyocyte population containing endothelial cells induced from each of iPS cells (201B7, 409B2, and 606A1) and ES cells (KhES1).FIG. 2C shows the results of subjecting HUVEC or the cells, which were sorted using miR-126-5p miRNA switch, to tube formation assay. -
FIG. 3A is a schematic diagram illustrating an miRNA switch containing two target sequences.FIG. 3B is the flow cytometry analysis results showing the percentage of CD31-positive cells or cTnT-positive cells in cells sorted using each miRNA switch (miR-126-3p+miR-208, miR-126-5p+miR-208, miR-208+miR-126-3p, miR-208+miR-126-5p, and miR-208) from cardiomyocytes and endothelial cells induced from iPS cells.FIG. 3C has graphs each showing the percentage of CD31-positive cells or cTnT-positive cells in cells sorted using each miRNA switch (miR-126-3p+miR-208, miR-126-5p+miR-208, miR-208+miR-126-3p, miR-208+miR-126-5p, and miR-208) from cardiomyocytes and endothelial cells induced from each of iPS cells (201B7 and 409B2) and ES cells (KhES1). -
FIG. 4A shows the results of comparing, using a microarray, the levels of expression of miRNAs between primary hepatocytes and fibroblasts (NHDF).FIG. 4B shows the flow cytometry analysis results obtained after each miRNA switch (containing control, miR-122-3p, miR-122-5p, miR-192-5p, miR-194-5p, and miR-215) together with EGFP was introduced into a hepatocyte population derived from induced differentiation of iPS cells. -
FIG. 5A shows the flow cytometry analysis results obtained after miR-122-5p miRNA switch together with EGFP was introduced into a hepatocyte population derived from induced differentiation of iPS cells.FIG. 5A also shows the flow cytometry analysis results obtained by gating the cells in the gate of the left panel, by staining them with an anti-ALUBUMIN or anti-HNF4A antibody, and by performing flow cytometry analysis.FIG. 5B is a graph showing the percentage of ALUBUMIN-positive cells or HNF4A-positive cells in: cells sorted using miR-122-5p miRNA switch from a hepatocyte population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-122-5p miRNA switch; and a hepatocyte population (w/o sort) derived from induced differentiation of the iPS cells.FIG. 5C shows the immunostaining results obtained by staining, with an anti-ALUBUMIN antibody, cells sorted using miR-122-5p miRNA switch from a hepatocyte population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-122-5p miRNA switch; and a hepatocyte population (w/o sort) derived from induced differentiation of the iPS cells. -
FIG. 6A shows the flow cytometry analysis results obtained after miR-375 miRNA switch together with EGFP was introduced into an insulin-producing cell population derived from induced differentiation of iPS cells.FIG. 6B is a graph showing the percentage of insulin-positive cells in: cells sorted, using miR-375 miRNA switch from an insulin-producing cell population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-375 miRNA switch; and an insulin-producing cell population (w/o sort) derived from induced differentiation of the iPS cells.FIG. 6C shows the immunostaining results obtained by staining, with an anti-insulin antibody, cells sorted using miR-375 miRNA switch from an insulin-producing cell population derived from induced differentiation of iPS cells; cells (negative fraction) other than the cells sorted using the miR-375 miRNA switch; and an insulin-producing cell population (w/o sort) derived from induced differentiation of the iPS cells. - The following describes, in detail, embodiments of the present invention. The present invention, however, is not limited to the following Embodiments.
- As used herein, the miRNA-responsive mRNA is also simply called an miRNA switch, and means an mRNA comprising the following nucleic acid sequences (i) and (ii): (i) a nucleic acid sequence specifically recognized by an miRNA; and (ii) a nucleic acid sequence corresponding to a coding region of a first marker gene. (i) The nucleic acid sequence specifically recognized by an miRNA and (ii) the nucleic acid sequence corresponding to a coding region of a first marker gene are operably linked.
- As used herein, the “miRNA” refers to a non-coding RNA composed of a short chain (20 to 25 bases) that is present in a cell and is participated in the regulation of gene expression through mRNA degradation and/or inhibition of translation from an mRNA to a protein. This miRNA is first produced as a transcribed, single-stranded pri-miRNA, an miRNA of which, together with its complementary strand, can form a hairpin loop structure; a portion of the pri-miRNA is cleaved by an enzyme called Drosha present in the nucleus to give a pre-miRNA, which is exported outside the nucleus; and the pre-miRNA is further cleaved by Dicer to become functional.
- The miRNA of (i) can be appropriately selected from an miRNA specifically expressed in a desired type of cell to be sorted. Examples of the desired type of cell include an endothelial cell, a hepatocyte, and an insulin-producing cell, as described below. The miRNA specifically expressed may be miRNAs, the expression levels of which are higher in a desired type of cell than in another type of cell by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more. Such an miRNA can be suitably selected from miRNAs registered on database information site (e.g., http://www.mirbase.org/ or http://www.microma.org/) and/or miRNAs described in literature disclosed in the database. Examples include, but are not limited to, miRNAs listed in Table 1.
-
TABLE 1 Table 1. miRNAs and the sequences thereof. miRNA name miRNA sequence (5′-3′) SEQ ID NO: miR-126-3P ucguaccgugaguaauaaugcg 1 miR-126-5P cauuauuacuuuugguacgcg 2 miR-122-5P uggagugugacaaugguguuug 3 miR-375 uuuguucguucggcucgcguga 4 - In the present invention, the nucleic acid sequence specifically recognized by an miRNA is preferably a sequence perfectly complementary to the miRNA. Alternatively, the nucleic acid sequence may have a mismatch in the perfectly complementary sequence as long as the nucleic acid sequence can be recognized by the miRNA. The mismatch may be a mismatch that the miRNA can usually recognize. Regarding in vivo, intracellular, intrinsic functions, the degree of the mismatch may be about 40 to 50%. Examples of such a mismatch include, but are not particularly limited to, 1 base, 2 bases, 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, and 10 bases; or 1% mismatch, 5% mismatch, 10% mismatch, 20% mismatch, 30% mismatch, and 40% mismatch per entire recognition sequence. In addition, like an miRNA target sequence included in a certain mRNA in a cell, many mismatches may be included in the 5′ region of a target sequence, which region is outside a seed region and corresponds to about 16 bases located on the 3′ side of the miRNA. The seed region may contain no mismatch or may contain mismatches: 1 base, 2 bases, or 3 bases. The length of such a sequence may be a base length corresponding to the number of bases that can bind specifically to RISC. The length of the sequence is preferably 18 bases or more and less than 24 bases and more preferably 20 bases or more and less than 22 bases. As used herein, a nucleic acid sequence specifically recognized by an miRNA may be used after determined by introducing an miRNA-responsive mRNA having the sequence into a desired type of cell and other cells; and by verifying that expression of a relevant marker gene is inhibited only in the desired type of cell. Examples of nucleic acid sequences specifically recognized by miR-126-3P, miR-126-5P, miR-122-5P, and miR-375 include, but are not limited to, target sequences listed in Table 2.
-
TABLE 2 Table 2. miRNAs and the target sequences thereof. SEQ miRNA name miRNA target sequence (5′-3′) ID NO: miR-126-3P CGCATTATTACTCACGGTACGA 5 miR-126-5P CGCGTACCAAAAGTAATAATG 6 miR-122-5P CAAACACCATTGTCACACTCCA 7 miR-375 TCACGCGAGCCGAACGAACAAA 8 - The (ii) “marker gene” used herein refers to a gene encoding any protein that functions as a marker after translation in a cell and enables cell sorting. Examples of a gene encoding the protein that functions as a marker after translation in a cell include, but are not limited to, genes encoding fluorescent proteins, light-emitting proteins, chromogenic proteins or fluorescence proteins; genes encoding proteins that help fluorescent proteins, etc., emit fluorescence, light, or color for visualization and quantification; and genes encoding proteins that kill cells when expressed (e.g., a membrane protein-encoding gene, an apoptosis-inducing gene, a suicide gene). In combination of an apoptosis-inducing gene, an apoptosis-inhibiting gene may be used as another marker gene. As used herein, a marker protein refers to a protein translated from an mRNA containing a nucleic acid corresponding to a coding region of the marker gene. As used herein, the term “first” is a term used to distinguish between two marker genes when used and is not restricted to a specific marker gene.
- Examples of the fluorescent protein include, but are not limited to, blue fluorescent proteins (e.g., Sirius, BFP, EBFP); cyan fluorescent proteins (e.g., mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, CFP); green fluorescent proteins (e.g., TurboGFP, AcGFP, TagGFP, Azami-Green (e.g., hmAG1), ZsGreen, EmGFP, EGFP, GFP2, HyPer); yellow fluorescent proteins (e.g., TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, mBanana); orange fluorescent proteins (e.g., KusabiraOrange (e.g., hmK02), mOrange); red fluorescent proteins (e.g., TurboRFP, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRed2, mStrawberry); and near-infrared fluorescent proteins (e.g., TurboFP602, mRFP1, JRed, KillerRed, mCherry, HcRed, KeimaRed (e.g., hdKeimaRed), mRasberry, mPlum).
- As used herein, examples of the light-emitting protein include, but are not limited to, Aequorin. In addition, examples of the protein that helps emit fluorescence, light, or color include, but are not limited to, enzymes that degrade fluorescent, light-emitting, or chromogenic precursors (e.g., luciferase, phosphatase, peroxidase, β-lactamase). As used herein, when a substance that helps emit fluorescence, light, or color is used as a substance encoded by a marker gene, a relevant precursor is made to contact a cell population or the relevant precursor is introduced into the cell population during target cell sorting.
- As used herein, the apoptosis-inducing gene means a gene encoding a protein having activity of inducing cellular apoptosis. Examples include, but are not limited to, IκB, Smac/DIABLO, ICE, HtrA2/OMI, AIF, endonuclease G, Bax, Bak, Noxa, Hrk (harakiri), Mtd, Bim, Bad, Bid, PUMA, activated caspase-3, Fas, and Tk. In the present invention, Bim is preferably used as the apoptosis-inducing gene.
- As used herein, a suicide gene is a gene, the cellular expression of which is lethal to the cell. As used herein, the suicide gene product (e.g., diphtheria toxin A), by itself, may cause cell death. In addition, expression of such a gene may make cells susceptible to a specific chemical (e.g., expression of herpes simplex virus thymidine kinase gene can make cells susceptible to an anti-virus compound). Examples of the suicide gene include, but are not limited to, genes encoding: diphtheria toxin A; herpes simplex virus thymidine kinase (HSV-TK); carboxypeptidase G2 (CPG2); carboxyl esterase (CA); cytosine deaminase (CD); cytochrome P450 (cyt-450); deoxycytidine kinase (dCK); nitroreductase (NR); purine-nucleoside phosphorylase (PNP); thymidine phosphorylase (TP); varicella-zoster virus thymidine kinase (VZV-TK); and xanthine-guanine phosphoribosyl transferase (XGPRT). In the present invention, the HSV-TK gene is preferably used as the suicide gene.
- As used herein, the marker gene may include a gene encoding a localization signal. Examples of the localization signal include a nuclear localization signal, a plasma membrane localization signal, a mitochondrial localization signal, and a protein secretion signal. Specific examples include, but are not limited to, a classical nuclear localization signal (NLS), M9 sequence, a mitochondrial target sequence (MTS), and an ER localization sequence. Such localization signals provide a particular advantage when imaging is used to carry out a step of sorting a target cell by, for example, imaging cytometry described below.
- As used herein, the phrase “a nucleic acid sequence specifically recognized by an miRNA is operably linked to a nucleic acid sequence corresponding to a coding region of a first marker gene” means that at least one miRNA target sequence is included in a 5′ UTR, a 3′ UTR of an open reading frame (including a start codon) encoding a marker gene and/or the open reading frame. An miRNA-responsive mRNA includes, preferably from the 5′ end, in the 5′ to 3′ direction, a cap structure (7-methylguanosine 5′-phosphate), and an open reading frame encoding a marker gene, and a poly-A tail, and also includes at least one miRNA target sequence in a 5′ UTR, a 3′ UTR, and/or the open reading frame. The position of the miRNA target sequence of the mRNA may be located at the 5′ UTR or 3′ UTR or located within the open reading frame (on the 3′ side of the start codon), all of which may each be provided with an miRNA target sequence. Hence, the number of the miRNA target sequences may be 1, 2, 3, 4, 5, 6, 7, 8, or more.
- Preferably, the nucleic acid sequences (i) and (ii) of the miRNA-responsive mRNA are linked from the 5′ to 3′ direction in this order. At this time, the number and kinds of bases between the cap structure and the miRNA target sequence may be freely chosen as long as the bases involve neither a stem structure nor a specific conformation. For instance, in some designs, the number of bases between the cap structure and the miRNA target sequence is from 0 to 50 and preferably from 10 to 30. In addition, the number and kinds of bases between the miRNA target sequence and the start codon may be freely chosen as long as the bases involve neither a stem structure nor a specific conformation. For instance, in some designs, the number of bases between the miRNA target sequence and the start codon is from 0 to 50 and preferably from 10 to 30.
- In the present invention, the miRNA target sequence of an miRNA-responsive mRNA preferably includes no AUG, a start codon. For example, when an miRNA target sequence is present in a 5′ UTR and the target sequence contains AUG, it is preferable to design such that the AUG is in the same frame of a marker gene linked on the 3′ side. Alternatively, when the target sequence contains AUG, the AUG in the target sequence may be changed to GUG. Further, to minimize the effect of AUG in the target sequence, the position of the target sequence in the 5′ UTR may be changed appropriately. For instance, in some position designs, the number of bases between the cap structure and the AUG sequence in the target sequence is from 0 to 60 such as from 0 to 15, from 10 to 20, from 20 to 30, from 30 to 40, from 40 to 50, and from 50 to 60.
- When an miRNA target sequence is present in a 5′ UTR in the present invention, the following sequences, for example, may be used.
-
TABLE 3 Table 3. miRNAs and the 5′ UTR sequences of corresponding miRNA-responsive mRNAs. 5′ UTR sequence (5′ -> 3′) in miRNA-responsive mRNA SEQ miRNA name (AUG at the 3′ end indicates a start codon) ID NO: miR-126-3P GGUUCCUUAAUCGCGGAUCCCGCAUUAUUACUCACGGUACGAAGAUCACAC 9 CGGUCGCCACCAUG miR-126-5P GGUUCCUUAAUCGCGGAUCCCGCGUACCAAAAGUAAUAAUGAGAUCACACC 1 0 GGUCGCCACCAUG miR-122-5P GGUUCCUUAAUCGCGGAUCCCAAACACCAUUGUCACACUCCAAGAUCACAC 1 1 CGGUCGCCACCAUG miR-375 GGUUCCUUAAUCGCGGAUCCUCACGCGAGCCGAACGAACAAAAGAUCACAC 1 2 CGGUCGCCACCAUG - When an miRNA target sequence is present in a 5′ UTR in the present invention, the following sequence, for example, may be used downstream (i.e., in a 3′ UTR) of a subsequent marker gene. At this time, any one of the above-described genes may be used as the marker gene interposed between the 5′ UTR and the 3′ UTR.
-
TABLE 4 UTR sequence 3′ UTR sequence SEQ ID NO: CCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGGCC 1 3 UUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUG GAAGGCAGAAACGACAUGGCCCUGAAGCUCGUGGGC GGGAGCCAUCUGAUCGCAAACAUCAAGACCACAUAU AGAUCCAAGAAACCCGCUAAGAACCUCAAGAUGCCU GGCGUCUACUAUGUGGACUACAGACUGGAAAGAAUC AAGGAGGCCAACAACGAGACCUACGUCGAGCAGCAC GAGGUGGCAGUGGCCAGAUACUGCGACCUCCCUAGC AAACUGGGGCACAGAUCUCAUAUGCAUCUCGAGUGA UAGUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCA UGCCCUUCUUCUCUCCCUUGCACCUGUACCUCUUGG UCUUUGAAUAAAGCCUGAGUAGGAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA - When a gene encoding BFP, for example, is used as a marker gene in the present invention, the following sequences may each be employed as a full-length miRNA-responsive mRNA according to the present invention.
-
TABLE 5 Table 5. miRNAs and the full-length sequences of corresponding miRNA-responsive mRNAs. Name of miRNA- responsive mRNA Full-lenghth miRNA-responsive mRNA SEQ ID NO: miR-126-3P GGUUCCUUAAUCGCGGAUCCCGCAUUAUUACUCACGGUACG 1 4 AAGAUCACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAU UAAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCG UGGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGC AAGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGU CGAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUA CUAGCUUCCUCUACGGCAGCAAGACCUUCAUCAACCACACC CAGGGCAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGG CUUCACAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCG UGCUGACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGC CUCAUCUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUC CAACGGCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGG CCUUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAA GGCAGAAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCA UCUGAUCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAAC CCGCUAAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGAC UACAGACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUA CGUCGAGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACC UCCCUAGCAAACUGGGGCACAGAUCUCAUAUGCAUCUCGAG UGAUAGUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUG CCCUUCUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGA AUAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAA miR-126-5P GGUUCCUUAAUCGCGGAUCCCGCGUACCAAAAGUAAUAAUG 1 5 AGAUCACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAUU AAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCGU GGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGCA AGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGUC GAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUAC UAGCUUCCUCUACGGCAGCAAGACCUUCAUCAACCACACCC AGGGCAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGGC UUCACAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCGU GCUGACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGCC UCAUCUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUCC AACGGCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGGC CUUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAAG GCAGAAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCAU CUGAUCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAACC CGCUAAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGACU ACAGACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUAC GUCGAGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACCU CCCUAGCAAACUGGGGCACAGAUCUCAUAUGCAUCUCGAGU GAUAGUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUGC CCUUCUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGAA UAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAA miR-122-5P GGUUCCUUAAUCGCGGAUCCCAAACACCAUUGUCACACUCC 1 6 AAGAUCACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAU UAAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCG UGGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGC AAGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGU CGAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUA CUAGCUUCCUCUACGGCAGCAAGACCUUCAUCAACCACACC CAGGGCAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGG CUUCACAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCG UGCUGACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGC CUCAUCUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUC CAACGGCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGG CCUUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAA GGCAGAAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCA UCUGAUCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAAC CCGCUAAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGAC UACAGACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUA CGUCGAGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACC UCCCUAGCAAACUGGGGCACAGAUCUCAUAUGCAUCUCGAG UGAUAGUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUG CCCUUCUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGA AUAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAA miR-375 GGUUCCUUAAUCGCGGAUCCUCACGCGAGCCGAACGAACAA 1 7 AAGAUCACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAU UAAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCG UGGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGC AAGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGU CGAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUA CUAGCUUCCUCUACGGCAGCAAGACCUUCAUCAACCACACC CAGGGCAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGG CUUCACAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCG UGCUGACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGC CUCAUCUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUC CAACGGCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGG CCUUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAA GGCAGAAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCA UCUGAUCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAAC CCGCUAAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGAC UACAGACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUA CGUCGAGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACC UCCCUAGCAAACUGGGGCACAGAUCUCAUAUGCAUCUCGAG UGAUAGUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUG CCCUUCUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGA AUAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAA - According to an embodiment of the present invention, an miRNA-responsive mRNA can be introduced as a form of DNA or mRNA.
- When the miRNA-responsive mRNA is introduced as a form of DNA, examples of a technique used to introduce the DNA into a somatic cell include use of vectors (e.g., a virus, a plasmid, an artificial chromosome), lipofection, liposome, and microinjection. Examples of the virus vector include a retrovirus vector, a lentivirus vector (e.g., Cell, 126, pp. 663-676, 2006; Cell, 131, pp. 861-872, 2007; Science, 318, pp. 1917-1920, 2007), an adenovirus vector (Science, 322, 945-949, 2008), an adeno-associated virus vector, and a sendaivirus vector (WO 2010/008054). Examples of the artificial chromosome vector include a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), and a bacterial artificial chromosome (BAC, PAC). As the plasmid, plasmids for mammalian cells may be used (Science, 322:949-953, 2008). In order to be able to express an miRNA-responsive mRNA, the vector may contain control sequences such as a promoter, an enhancer, a ribosome binding sequence, a terminator, and a polyadenylation site. Also, the vector, if needed, may further contain: a drug resistance gene (e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene); a selection marker sequence (e.g., a thymidine kinase gene, a diphtheria toxin gene); and/or a reporter gene sequence (e.g., genes encoding green fluorescent protein (GFP), β-glucuronidase (GUS), FLAG).
- When the miRNA-responsive mRNA is the form of RNA, examples of a technique for introducing the mRNA into a somatic cell include lipofection and microinjection. To suppress degradation, 5-methylcytidine and/or pseudouridine (TriLink Biotechnologies) may be incorporated into the RNA to be used (Warren L, (2010) Cell Stem Cell. 7: 618-630). Regarding the positions of modified bases, all or some of uridines or cytidines may be replaced by the modified base independently. When some of them are replaced, the percentage of the modified base may be freely chosen and the position or positions may be at random.
- Two or more different miRNA-responsive mRNAs may be introduced. Alternatively, an miRNA-responsive mRNA and an mRNA as a control (hereinafter, sometimes referred to as a control mRNA) as described below may be introduced. In such cases, multiple mRNAs are preferably co-introduced. The ratio between two or more co-introduced mRNAs can be maintained in individual cells. So, the activity ratio between proteins expressed using these mRNAs can be also maintained in a corresponding cell population. At this time, the amount of each mRNA introduced varies depending on a cell population into which the mRNAs are introduced, the mRNAs introduced, and a method and reagent for the introduction, and may be suitably selected by those skilled in the art so as to achieve a desired level of translation thereof.
- According to an embodiment of the present invention, a control mRNA, for example, consists of a sequence comprising a nucleic acid corresponding to a coding region of a marker gene or a sequence comprising a nucleic acid corresponding to a coding region of a drug resistance gene, and does not have an miRNA target site. According to a preferable embodiment, the control mRNA together with an miRNA-responsive mRNA is introduced into a cell population. Then, the control mRNA can function as a control for identifying and distinguishing a cell containing the miRNA-responsive mRNA from others. In addition, the control mRNA can also function as a control used when a level of signal (e.g., fluorescence and light) from the miRNA-responsive mRNA is quantified. The amount of the control mRNA introduced may be suitably selected by those skilled in the art so as to achieve a desired level of translation thereof.
- Regarding the “drug resistance gene” as used herein, it is possible to use any gene that can express a protein resistant to a corresponding drug. Examples include, but are not limited to, antibiotic resistance genes. Examples of the antibiotic resistance gene include a kanamycin resistance gene, an ampicillin resistance gene, a puromycin resistance gene, a blasticidin resistance gene, a gentamicin resistance gene, a kanamycin resistance gene, a tetracycline resistance gene, and a chloramphenicol resistance gene. According to the present invention, a puromycin resistance gene or a blasticidin resistance gene is preferably used as the antibiotic resistance gene.
- A sorting method according to an embodiment of the present invention more preferably includes a step of simultaneously introducing an miRNA-responsive mRNA and a control mRNA into a cell population containing a target cell. The step may be preferably performed by co-transfecting the miRNA-responsive mRNA and the control mRNA. Use of the control mRNA allows for sorting of, as a target cell, a cell in which a marker protein is less or hardly translated from the miRNA-responsive mRNA even if the efficiency of introducing the miRNA-responsive mRNA into cells is low.
- According to the present invention, when a control mRNA is used, a marker gene included in the control mRNA is preferably different from a marker gene included in an miRNA-responsive mRNA. For instance, when the marker gene included in an miRNA-responsive mRNA is an apoptosis-inducing gene or a suicide gene, the marker gene included in the control mRNA may be a fluorescent protein-encoding gene. In this case, fluorescent cells are subjected to, for example, FACS sorting for selective separation. Then, cells with reduced levels of expression of the apoptosis-inducing gene or the suicide gene are sorted as target cells. This can improve sorting precision.
- In addition, a control mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of a drug resistance gene can be used with an miRNA-responsive mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of any marker gene. In this case, cells containing the miRNA-responsive mRNA are resistant to the drug regardless of the kind of the marker gene, which can improve sorting precision.
- In contrast, the same type of gene may be used for marker genes included in an miRNA-responsive mRNA and a control mRNA. For instance, fluorescent protein-encoding genes may be used for the marker genes included in an miRNA-responsive mRNA and a control mRNA. In this case, two corresponding fluorescent proteins should have different fluorescence wavelengths.
- Note that the fluorescent protein-encoding gene may be replaced by a gene encoding a light-emitting protein or a protein that helps emit fluorescence, light, or color, which gene is likewise used in combination.
- Examples of a control mRNA that can be used according to the present invention include, but are not particularly limited to, the following mRNAs.
-
TABLE 6-1 Table 6. Control mRNAs Control mRNA Sequence SEQ ID NO: mRNA_tagBFP GGGCGAAUUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAA 1 8 GACACCGGUCGCCACCAUGGGAUCCAGCGAGCUGAUUAAGG AGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCGUGGAC AACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGCAAGCC CUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGUCGAGG GCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUACUAGC UUCCUCUACGGCAGCAAGACCUUCAUCAACCACACCCAGGG CAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGGCUUCA CAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCGUGCUG ACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGCCUCAU CUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUCCAACG GCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGGCCUUC ACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAAGGCAG AAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCAUCUGA UCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAACCCGCU AAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGACUACAG ACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUACGUCG AGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACCUCCCU AGCAAACUGGGGCACAGAUCUCAUAUGCAUCUCGAGUGAUA GUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUGCCCUU CUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGAAUAAA GCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAA mRNA_EGFP GGGCGAAUUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAA 1 9 GACACCGGUCGCCACCAUGGGAUCCGUGAGCAAGGGCGAGG AGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGAC GGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGG CGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCA UCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUC GUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUA CCCCGACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCA UGCCCGAAGGCUACGUCCAGGAGCGCACCAUCUUCUUCAAG GACGACGGCAACUACAAGACCCGCGCCGAGGUGAAGUUCGA GGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGGCAUCG ACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGAG UACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAA GCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACA ACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCAG CAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGA CAACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACC CCAACGAGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUG ACCGCCGCCGGGAUCACUCUCGGCAUGGACGAGCUGUACAA GAGAUCUCAUAUGCAUCUCGAGUGAUAGUCUAGACCUUCUG CGGGGCUUGCCUUCUGGCCAUGCCCUUCUUCUCUCCCUUGC ACCUGUACCUCUUGGUCUUUGAAUAAAGCCUGAGUAGGAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA mRNA_Blastcidin GGGCGAAUUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAA 2 0 GACACCGGUCGCCACCAUGGCCAAGCCUUUGUCUCAAGAAG AAUCCACCCUCAUUGAAAGAGCAACGGCUACAAUCAACAGC AUCCCCAUCUCUGAAGACUACAGCGUCGCCAGCGCAGCUCU CUCUAGCGACGGCCGCAUCUUCACUGGUGUCAAUGUAUAUC AUUUUACUGGGGGACCUUGUGCAGAACUCGUGGUGCUGGGC ACUGCUGCUGCUGCGGCAGCUGGCAACCUGACUUGUAUCGU CGCGAUCGGAAAUGAGAACAGGGGCAUCUUGAGCCCCUGCG GACGGUGCCGACAGGUGCUUCUCGAUCUGCAUCCUGGGAUC AAAGCCAUAGUGAAGGACAGUGAUGGACAGCCGACGGCAGU UGGGAUUCGUGAAUUGCUGCCCUCUGGUUAUGUGUGGGAGG GCUAAUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUGC CCUUCUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGAA UAAAGCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAA mRNA_Puromycin GGGCGAAUUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAA 2 1 GACACCGGUCGCCACCAUGACCGAGUACAAGCCCACGGUGC GCCUCGCCACCCGCGACGACGUCCCCCGGGCCGUACGCACC CUCGCCGCCGCGUUCGCCGACUACCCCGCCACGCGCCACAC CGUCGAUCCGGACCGCCACAUCGAGCGGGUCACCGAGCUGC AAGAACUCUUCCUCACGCGCGUCGGGCUCGACAUCGGCAAG GUGUGGGUCGCGGACGACGGCGCCGCGGUGGCGGUCUGGAC CACGCCGGAGAGCGUCGAAGCGGGGGCGGUGUUCGCCGAGA UCGGCCCGCGCAUGGCCGAGUUGAGCGGUUCCCGGCUGGCC GCGCAGCAACAGAUGGAAGGCCUCCUGGCGCCGCACCGGCC CAAGGAGCCCGCGUGGUUCCUGGCCACCGUCGGCGUCUCGC CCGACCACCAGGGCAAGGGUCUGGGCAGCGCCGUCGUGCUC CCCGGAGUGGAGGCGGCCGAGCGCGCCGGGGUGCCCGCCUU CCUGGAGACCUCCGCGCCCCGCAACCUCCCCUUCUACGAGC GGCUCGGCUUCACCGUCACCGCCGACGUCGAGGUGCCCGAA GGACCGCGCACCUGGUGCAUGACCCGCAAGCCCGGUGCCUG AUCUAGACCUUCUGCGGGGCUUGCCUUCUGGCCAUGCCCUU CUUCUCUCCCUUGCACCUGUACCUCUUGGUCUUUGAAUAAA GCCUGAGUAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAA - A sorting method according to an embodiment of the present invention may comprise a step of introducing an miRNA-responsive mRNA and an optional control mRNA into a cell population. This step allows a target type of cell to be sortable from the cell population containing the target type of cell. Specifically, this step enables a desired type of cell to provide detectable signal information different from signal information of the other types of cell in the cell population containing two or more types of cell optionally including the target type of cell. In the below-described production protocols, the sorting step may further be carried out to selectively separate the target type of cell.
- As used herein, endothelial cells are squamous thin cells constituting the inner surface of a blood vessel and are not distinguished from endothelial precursor cells in the present invention. Endothelial cells used in the present invention may be continuously cultured to form a tubular structure. Preferably, the cells can take up acetylated low-density-lipoproteins (ac-LDL). The endothelial cells are characterized by expression of a marker including, without particular limitation, CD31, etc.
- In the present invention, a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting an endothelial cell is preferably a nucleic acid sequence specifically recognized by miR-126-3P or miR-126-5P.
- A cell population that is subject to sorting may contain any cell population that can contain endothelial cells. For instance, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto. Thus, it may be possible that an miRNA-responsive mRNA is introduced into a cell population that may or may not contain endothelial cells. In a preferable embodiment, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell. Such induced differentiation is not limited to specific induction into endothelial cells, and may include induced differentiation for the purpose of obtaining another type of cell such as cardiomyocytes.
- A protocol for producing endothelial cells from a pluripotent stem cell may be appropriately performed, including, for example, the known procedure (Li et al., J. Cell Biochem., 106: 194-199, 2009).
- As used herein, hepatocytes are defined as cells expressing an mRNA of albumin or HNF4A. According to another embodiment of the present invention, hepatocytes are defined as cells characterized by any one or combination of known hepatocyte functions such as glycogen accumulation, low-density-lipoprotein (LDL) incorporation, albumin secretion, ammonia metabolism and urea synthesis, cytochrome P450 activity, lipid metabolism, and drug metabolism.
- In the present invention, a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting a hepatocyte is preferably a nucleic acid sequence specifically recognized by miR-122-5P.
- A cell population that is subject to sorting may contain any cell population that can contain hepatocytes. For instance, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto. Thus, it may be possible that an miRNA-responsive mRNA is introduced into a cell population that may or may not contain hepatocytes. In a preferable embodiment, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell. Such induced differentiation is not limited to specific induction into hepatocytes.
- A protocol for producing hepatocytes from a pluripotent stem cell may be appropriately performed, including the known procedures (e.g., WO2001/081549; Takayama K, et al., Stem Cell Reports. 1: 322-335, 2013; Kajiwara M, et al., Proc Natl Acad Sci USA. 109: 12538-12543, 2012; Hay D C, et al., Stem Cells. 26: 894-902, 2008).
- Insulin-Producing Cell Sorting Method
- As used herein, insulin-producing cells are defined as cells expressing an mRNA of insulin.
- In the present invention, a nucleic acid sequence that is specifically recognized by an miRNA and is contained in an miRNA-responsive mRNA used for sorting an insulin-producing cell is preferably a nucleic acid sequence specifically recognized by miR-375.
- A cell population that is subject to sorting may contain any cell population that can contain insulin-producing cells. For instance, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell or may be an in vivo cell population, but is not limited thereto. Thus, it may be possible for an miRNA-responsive mRNA to be introduced into a cell population that may or may not contain insulin-producing cells. In a preferable embodiment, the cell population may be a cell population that has been induced to differentiate from a pluripotent stem cell. Such induced differentiation is not limited to specific induction into insulin-producing cells.
- Examples of a protocol for inducing insulin-producing cells from a pluripotent stem cell include methods for induced differentiation using activin and/or retinoic acid (RA) (Japanese Patent Laid-Open No. 2009-225661, E. Kroon et al., Nature Biotechnology (2008) Vol. 26, No. 4: 443-452, K. A. D'Amour et al., Nature Biotechnology (2006) Vol. 24, No. 11: 1392-1401, W. Jiang, Cell Research (2007) 17: 333-344, J. H. Shim et al., Diabetologia (2007) 50: 1228-1238, R. Maehra et al., PNAS (2009), vol. 106, No. 37: 15768-15773). Additional examples include: methods including introducing PDX1 into a pluripotent stem cell and culturing the cell (U.S. Pat. No. 7,534,608 and Japanese Patent Laid-Open No. 2006-075022); and methods for producing insulin-producing cells by applying a suitable combination of low-molecular-weight compounds to a pluripotent stem cell (WO2011/081222 and Kunisada Y et al., Stem Cell Res. (2012) vol. 8, No. 2: 274-284).
- As used herein, a pluripotent stem cell is a stem cell that is pluripotent and can differentiate into many types of cells in vivo and can also self-replicate, and includes any type of cell that can be induced into hepatocytes used in the present invention. Examples of the pluripotent stem cell include, but are not particularly limited to, an embryonic stem (ES) cell, a nuclear transfer-mediated clone embryo-derived embryonic stem (ntES) cell, a germline stem cell (“GS cell”), an embryonic germ cell (“EG cell”), an induced pluripotent stem (iPS) cell, and a fibroblast or bone marrow stem cell-derived pluripotent cell (Muse cell). A preferable pluripotent stem cell is an iPS cell and more preferably a human iPS cell from the viewpoint that the cell is available without destroying an embryo or an egg, etc., during production thereof.
- (A) Embryonic Stem Cell
- An embryonic stem cell (ES cell) is a stem cell that has been established from an inner cell mass of an early embryo (e.g., a blastocyst) of a mammal such as a human and a mouse and that is pluripotent and can self-replicate.
- The ES cell is an embryonic stem cell derived from an inner cell mass of a blastocyst, an embryo after an 8-cell stage and morula of a fertilized egg, and has an ability to differentiate into all the cells constituting an adult body, what is called pluripotency, and can self-replicate. The ES cell was discovered in a mouse in 1981 (M. J. Evans and M. H. Kaufman (1981), Nature 292: 154-156). Later, ES cell lines were established in primates such as a human and a monkey (J. A. Thomson et al. (1998), Science 282: 1145-1147; J. A. Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92: 7844-7848; J. A. Thomson et al. (1996), Biol. Reprod., 55: 254-259; J. A. Thomson and V. S. Marshall (1998), Curr. Top. Dev. Biol., 38: 133-165).
- An ES cell can be established by isolating an inner cell mass from a blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder layer. The cells can be maintained by splitting the culture using a culture medium containing, for example, leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF). Human and monkey ES cells have been established and maintained in accordance with the procedures described in, for example, U.S. Pat. No. 5,843,780; Thomson J A, et al. (1995), Proc Natl. Acad. Sci. USA. 92: 7844-7848; Thomson J A, et al. (1998), Science. 282: 1145-1147; H. Suemori et al. (2006), Biochem. Biophys. Res. Commun., 345: 926-932; M. Ueno et al. (2006), Proc. Natl. Acad. Sci. USA, 103: 9554-9559; H. Suemori et al. (2001), Dev. Dyn., 222: 273-279; H. Kawasaki et al. (2002), Proc. Natl. Acad. Sci. USA, 99: 1580-1585; Klimanskaya I, et al. (2006), Nature. 444: 481-485.
- As a culture medium for producing an ES cell, it is possible to use DMEM/F-12 culture medium supplemented with, for example, 0.1 mM 2-mercaptoethanol, 0.1 mM non-essential amino acids, 2 mM L-glutamine, 20% KSR, and 4 ng/ml bFGF. Then, the human ES cell can be maintained at 37° C. and 5% CO2 under a humid atmosphere (H. Suemori et al. (2006), Biochem. Biophys. Res. Commun., 345: 926-932). In addition, the ES cells should be divided every 3 to 4 days. At this time, the cells may be divided using, for example, 0.25% trypsin and 0.1 mg/ml collagenase IV in PBS containing 1 mM CaCl2 and 20% KSR.
- The ES cells can be selected, in general, by a real-time PCR method using, as an indicator, expression of gene markers such as alkaline phosphatase, Oct-3/4, and Nanog genes. Especially, human ES cells can be selected by using, as an indicator, expression of gene markers such as OCT-3/4, NANOG, and ECAD genes (E. Kroon et al. (2008), Nat. Biotechnol., 26: 443-452).
- Regarding human ES cell lines, for example, WA01 (H1) and WA09 (H9) are available from WiCell Research Institute and KhES-1, KhES-2, and KhES-3 are available from the Institute for Frontier Medical Sciences, Kyoto University (Kyoto, Japan).
- (B) Germline Stem Cell
- The germline stem cell is a testis-derived pluripotent stem cell, which is a source of spermatogenesis. This cell, like the ES cell, can be induced to differentiate into various cell lineages, characterized in that when this cell is transplanted in a mouse blastocyst, for example, a chimeric mouse can be generated (M. Kanatsu-Shinohara et al. (2003) Biol. Reprod., 69:612-616; K. Shinohara et al. (2004), Cell, 119: 1001-1012). This cell can self-replicate in a culture medium containing glial cell line-derived neurotrophic factor (GDNF). In addition, after repeated cell passages under substantially the same culture conditions as of ES cells, a germline stem cell can be obtained (Masanori Takebayashi et al. (2008), “Jikken Igaku (Experimental Medicine)”, vol. 26, no. 5 (special issue), pages 41-46, YODOSHA CO., LTD. (Tokyo, Japan)).
- (C) Embryonic Germ Cell
- The embryonic germ cell has been established from an embryonic primordial germ cell and, like an ES cell, is pluripotent. Also, an embryonic germ cell can be established by culturing a primordial germ cell in the presence of substances such as LIF, bFGF, and stem cell factor (Y. Matsui et al. (1992), Cell, 70: 841-847; J. L. Resnick et al. (1992), Nature, 359: 550-551).
- (D) Induced Pluripotent Stem Cell
- An induced pluripotent stem (iPS) cell can be created by introducing, as a form of DNA, RNA, or protein, specific reprogramming factors into a somatic cell, and is a somatic cell-derived induced stem cell that has substantially the same properties as of an ES cell, namely a cell having pluripotency and ability to self-replicate (K. Takahashi and S. Yamanaka (2006) Cell, 126: 663-676; K. Takahashi et al. (2007), Cell, 131: 861-872; J. Yu et al. (2007), Science, 318: 1917-1920; Nakagawa, M. et al., Nat. Biotechnol. 26:101-106 (2008); WO 2007/069666). The reprogramming factors may be composed of genes that are specifically expressed in an ES cell, the products or non-coding RNAs thereof, genes that play a critical role in keeping an ES cell undifferentiated, the products or non-cording RNAs thereof, and/or low-molecular-weight compounds. Examples of genes included in the reprogramming factors include Oct3/4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 and Glis 1. These reprogramming factors may be used alone or in combination. The combinations of the reprogramming factors are exemplified and described in WO2007/069666, WO2008/118820, WO2009/007852, WO2009/032194, WO2009/058413, WO2009/057831, WO2009/075119, WO2009/079007, WO2009/091659, WO2009/101084, WO2009/101407, WO2009/102983, WO2009/114949, WO2009/117439, WO2009/126250, WO2009/126251, WO2009/126655, WO2009/157593, WO2010/009015, WO2010/033906, WO2010/033920, WO2010/042800, WO2010/050626, WO 2010/056831, WO2010/068955, WO2010/098419, WO2010/102267, WO 2010/111409, WO 2010/111422, WO2010/115050, WO2010/124290, WO2010/147395, WO2010/147612, Huangfu D, et al. (2008), Nat. Biotechnol., 26: 795-797, Shi Y, et al. (2008), Cell Stem Cell, 2: 525-528, Eminli S, et al. (2008), Stem Cells. 26: 2467-2474, Huangfu D, et al. (2008), Nat Biotechnol. 26: 1269-1275, Shi Y, et al. (2008), Cell Stem Cell, 3, 568-574, Zhao Y, et al. (2008), Cell Stem Cell, 3: 475-479, Marson A, (2008), Cell Stem Cell, 3, 132-135, Feng B, et al. (2009), Nat Cell Biol. 11: 197-203, R. L. Judson et al., (2009), Nat. Biotech., 27: 459-461, Lyssiotis C A, et al. (2009), Proc Natl Acad Sci USA. 106: 8912-8917, Kim J B, et al. (2009), Nature. 461: 649-643, Ichida J K, et al. (2009), Cell Stem Cell. 5: 491-503, Heng J C, et al. (2010), Cell Stem Cell. 6: 167-74, Han J, et al. (2010), Nature. 463: 1096-100, Mali P, et al. (2010), Stem Cells. 28: 713-720, Maekawa M, et al. (2011), Nature. 474: 225-9.
- Regarding the reprogramming factors, examples of a factor that is used to increase the establishment efficiency include: histone deacetylase (HDAC) inhibitors [e.g., low-molecular-weight inhibitors such as valproic acid (VPA), trichostatin A, sodium butyrate, MC 1293, M344; nucleic acid expression inhibitors such as siRNAs and shRNAs against HDAC (e.g., HDAC1 siRNA Smartpool (a registered trademark) (Millipore), HuSH 29mershRNA Constructs against HDAC1 (OriGene))]; MEK inhibitors (e.g., PD184352, PD98059, U0126, SL327, and PD0325901); glycogen synthase kinase-3 inhibitors (e.g., Bio and CHIR99021); DNA methyltransferase inhibitors (e.g., 5-azacytidine); histone methyltransferase inhibitors (e.g., low-molecular-weight inhibitors such as BIX-01294; nucleic acid expression inhibitors such as siRNAs and shRNAs against Suv39h1, Suv39h2, SetDB1, and G9a); L-channel calcium agonists (e.g., Bayk8644); butyric acid; TGF-β inhibitors or ALK5 inhibitors (e.g., LY364947, SB431542, 616453, and A-83-01); p53 inhibitors (e.g., siRNAs and shRNA against p53); ARID3A inhibitors (e.g., siRNAs and shRNAs against ARID3A); miRNAs such as miR-291-3p, miR-294, miR-295, and mir-302; Wnt signaling molecules (e.g., soluble Wnt3a); neuropeptide Y; prostaglandins (e.g., prostaglandin E2 and prostaglandin J2); and hTERT, SV40LT, UTF1, IRX6, GLIS1, PITX2, and DMRTB1. As used herein, unless otherwise indicated, these factors that are used to improve the establishment efficiency are included in the reprogramming factors.
- The reprogramming factors may be introduced into a somatic cell by using technology such as lipofection, fusion to a cell penetrating peptide (e.g., HIV-derived TAT and polyarginine), and microinjection in the form of protein.
- In the case of using a DNA form, examples of a technique used to introduce the reprogramming factors into a somatic cell include use of vectors (e.g., a virus, a plasmid, an artificial chromosome), lipofection, liposome, and microinjection. Examples of the virus vector include a retrovirus vector, a lentivirus vector (e.g., Cell, 126, pp. 663-676, 2006; Cell, 131, pp. 861-872, 2007; Science, 318, pp. 1917-1920, 2007), an adenovirus vector (Science, 322, 945-949, 2008), an adeno-associated virus vector, and a sendaivirus vector (WO 2010/008054). Examples of the artificial chromosome vector include a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), and a bacterial artificial chromosome (BAC, PAC). As the plasmid, plasmids for mammalian cells may be used (Science, 322:949-953, 2008). In order to be able to express nuclear reprogramming substances, the vector may contain a promoter, an enhancer, a ribosome binding sequence, a terminator, a poly-A site. Also, the vector, if needed, may further contain: a drug resistance gene (e.g., a kanamycin resistant gene, an ampicillin resistance gene, a puromycin resistance gene); a selection marker sequence (e.g., a thymidine kinase gene, a diphtheria toxin gene); and/or a reporter gene sequence (e.g., genes encoding green fluorescent protein, β-glucuronidase (GUS), FLAG). In addition, to remove a reprogramming factor-encoding gene, or a promoter and a reprogramming factor-encoding gene linked to the promoter together after the introduction into a somatic cell, the vector may contain LoxP motifs before and after the sequence.
- In the case of an RNA form, a technique such as lipofection and microinjection may be used to introduce the reprogramming factors into a somatic cell. To reduce their degradation, RNA containing 5-methylcytidine and pseudouridine (TriLink Biotechnologies) may be used (Warren L, (2010) Cell Stem Cell. 7: 618-630).
- Examples of a culture medium for iPS cell induction include: 10 to 15% FBS-containing DMEM and DMEM/F12 or DME culture medium (these culture media optionally further containing LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, β-mercaptoethanol, etc.); and commercially available culture media [e.g., mouse ES cell culture medium (TX-WES culture medium; Thromb-X N.V.), primate ES cell culture medium (primate ES/iPS cell culture medium; ReproCELL Inc.), serum-free media (mTeSR, Stemcell Technology, Inc.; Essential 8, Life Technologies, Inc.; StemFit, Ajinomoto, Inc.)].
- For example, a culture protocol includes: causing reprogramming factors to contact somatic cells in 10% FBS-containing DMEM or DMEM/F12 culture medium at 37° C. in the presence of 5% CO2 and culturing the cells for about 4 to 7 days, and thereafter; plating the cells on a feeder cell (e.g., mitomycin C-treated STO cell, SNL cell, etc.) layer; and culturing, from about 10 days after the contact between the somatic cells and the reprogramming factors, the resulting cells in bFGF-containing primate ES cell culture medium, so that iPS-like colonies can be generated at about 30 to about 45 days or later after the contact.
- Alternatively, the relevant cells are cultured on a feeder cell (e.g., mitomycin C-treated STO cell, SNL cell, etc.) layer in 10% FBS-containing DMEM culture medium (further optionally containing LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, β-mercaptoethanol, etc.) at 37° C. in the presence of 5% CO2, so that ES-like colonies can be generated after about 25 to about 30 days or later. In a desirable protocol, instead of the feeder cells, for example, somatic cells that are subject to reprogramming are used (Takahashi K, et al. (2009), PLoS One. 4: e8067 or WO2010/137746) or an extracellular matrix (e.g., Laminin-5 (WO2009/123349), Matrigel (BD, Inc.), or iMatrix511 (Nippi, Inc.)) is used.
- Other examples include a culturing protocol using a serum-free medium (Sun N, et al. (2009), Proc Natl Acad Sci USA. 106:15720-15725). In addition, to increase the establishment efficiency, an iPS cell may be established in a low oxygen condition (i.e., the level of oxygen of from 0.1% or more to 15% or less) (Yoshida Y, et al. (2009), Cell Stem Cell. 5: 237-241 or WO2010/013845)
- During the culturing, the culture medium is changed to a fresh medium once a day from day 2 after initiation of the culture. In addition, the number of somatic cells used for nuclear reprogramming has no limitation and ranges from about 5×103 to about 5×106 cells per 100 cm2 culture dish.
- The iPS cell can be selected in accordance with the morphology of a colony formed. In addition, the iPS cell can be selected using, as indicators, genes (e.g., SSEA-1, SSEA-3, SSEA-4, TRA-2-54, TRA-1-60, and TRA-1-80) that are expressed when somatic cells are reprogrammed.
- As used herein, the term “somatic cell” refers to any animal cell (preferably, mammalian cells, including human cells) excluding reproductive cells (e.g., an egg cell, an oocyte, an ES cell) or totipotent cells. Examples of the somatic cell include, without limitation, any of fetal somatic cells, neonatal somatic cells, and mature, healthy or disease somatic cells. Additional examples include any of primary culture cells, subcultured cells, and cell lines. Specific examples of the somatic cell include: (1) tissue stem cells (somatic stem cells) such as a neural stem cell, a hematopoietic stem cell, a mesenchymal stem cell, a dental pulp stem cell; (2) tissue precursor cells; and (3) differentiated cells such as a lymphocyte, an epithelial cell, an endothelial cell, a myocyte, a fibroblast (e.g., a skin cell, etc.), a hair cell, a hepatocyte, a gastric mucosa cell, an intestinal cell, a splenocyte, a pancreatic cell (e.g., a pancreatic exocrine cell, etc.), a brain cell, a pneumocyte, a nephrocyte, and an adipocyte.
- Meanwhile, when the iPS cells are used as a transplantable cell material, it is desirable from the viewpoint of there being no occurrence of rejection to use somatic cells having the same or substantially the same HLA genotype as of an individual that is subject to transplantation. Here, the term “substantially the same” means that the HLA genotype is matched to such an extent that the immune reaction against the transplanted cells can be suppressed by an immunosuppressive agent. For example, the somatic cells have an HLA genotype in which three gene loci: HLA-A, HLA-B, and HLA-DR are identical or four gene loci including an additional HLA-C are identical.
- (E) ES Cell Derived from Nuclear Transfer-Mediated Clone Embryo
- A nuclear transfer-mediated clone embryo-derived ES cell (nt ES cell) is an ES cell that is derived from a clone embryo generated using a nuclear transfer technique and has substantially the same properties as of a fertilized egg-derived ES cell (T. Wakayama et al. (2001), Science, 292:740-743; S. Wakayama et al. (2005), Biol. Reprod., 72:932-936; J. Byrne et al. (2007), Nature, 450:497-502). That is, the nt ES (nuclear transfer ES) cell is an ES cell that has been established from an inner cell mass of a blastocyst of a clone embryo as obtained by switching the nucleus of an unfertilized egg to the nucleus of a somatic cell. To generate an nt ES cell, a nuclear transfer technique (J. B. Cibelli et al. (1998), Nature Biotechnol., 16:642-646) and ES cell creation technology are combined (Sayaka Wakayama (2008), “Jikken Igaku (Experimental Medicine)”, vol. 26, no. 5 (special issue), pages 47-52). During the nuclear transfer, the nucleus of a somatic cell is injected into an enucleated unfertilized egg of a mammal and the resulting egg is cultured for reprogramming for several hours.
- (F) Multilineage-Differentiating Stress Enduring Cell
- The multilineage-differentiating stress enduring cell (Muse cell) is a pluripotent stem cell as generated by the protocol described in WO2011/007900. Specifically, fibroblasts or bone marrow stromal cells are treated with trypsin for an extended period and, preferably, the cells are treated for 8 or 16 h; and the cells are then subjected to suspension culture to yield pluripotent cells that are positive for SSEA-3 and CD105.
- Cells sorted by the present invention may be administered pharmaceutically. Hence, provided is a therapeutic agent containing cells sorted by a method of the present invention. When the cells sorted are endothelial cells, the cells may be administered for treatment of patients with severe ischemia including coronary artery disease and lower limb ischemia (e.g., Buerger disease, arteriosclerosis obliterans, etc.). Hence, an embodiment of the present invention provides a vascular regeneration promoter containing endothelial cells sorted by the above-described method. When the cells sorted are hepatocytes, the cells may be administered for treatment of liver failure such as chronic liver failure (e.g., hepatic cirrhosis) and acute liver failure. Hence, an embodiment of the present invention provides a liver disease drug containing hepatocytes obtained by the above-described method. When the cells sorted are insulin-producing cells, the cells may be administered for treatment of diabetes mellitus, in particular, type 1 diabetes. Hence, an embodiment of the present invention provides a diabetes drug containing insulin-producing cells obtained by the above-described method. The number of cells administered has no particular limitation as long as the dose can exert an advantageous effect on treatment. The cells may be prepared by appropriately adjusting the number depending on the size of a lesion and/or the body size.
- miRNA Switch Construction
- PCR Primers
- Table 7 lists PCR primers used below.
-
TABLE 7 Primer name Sequence (5′->3′) TagBFP_Tfwd GCCACCATGGGATCCAGCGAGCTGATTAAGGAGAAC TagBFP_Trev ACTCGAGATCTGTGCCCCAGTTTGCTAG pGEMTAP_MCS_Rev GGGATCCCATGGTGTCGACCTGCAGCATATGAGCTCCTGAATT CGCCCTATAGTGAGTCG pGEMTAP_MCS_Fwd GGGAGATCTCATATGCATCTCGAGTGATAGTCTAGACAAGCTT GAGTATTCTATAGTGTCACC YF128_EXFP_Tfwd GAACCATGGGATCCGTGAGCAAGGGCGAGG YF129_EXFP_Trev TATGAGATCTCTTGTACAGCTCGTCCATG tagBFP fwd CACCGGTCGCCACCATGGGATCCAGCGAG TAPEGFP_IVTfwd CACCGGTCGCCACCATGGGATCCGTGAGCAAGGGC TAP_IVTrev GCCCCGCAGAAGGTCTAGACTATCACTCGAGATGCATATGAGA TC TAP_T7_G3C fwd primer CAGTGAATTGTAATACGACTCACTATAGGGC Rev5UTR primer CATGGTGGCGACCGGTGTCTTATATTTCTTCTTACTC Fwd3UTR primer TCTAGACCTTCTGCGGGGC Rev3UTR2T20 TTTTTTTTTTTTTTTTTTTTCCTACTCAGGCTTTATTCAAAGA CCAAG 3UTR120A rev primer TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCTACTCAG GCTTTATTCA - Template Plasmid DNA
- (a) pTAP-tagBFP
- A fragment was amplified by PCR method using pTagBFP-Tubulin (evrogen) as a template and TagBFP_Tfwd and TagBFP_Trev as primers. The resulting fragment was inserted into pGEM-TAP, a cloning vector originally constructed by the inventors. The pGEM-TAP was constructed by PCR mutagenesis using pGEM-Teasy (Promega) as a template and pGEMTAP_MCS_Rev and pGEMTAP_MCS_Fwd as primers.
- (b) pCTp-EGFP
- A fragment was amplified by PCR method using pEGFP-N1 (Clontech) as a template and YF128_EXFP_Tfwd and YF129_EXFP_Trev as primers. The resulting fragment was inserted into pCM-TAP, a cloning vector originally constructed by the inventors. The pCM-TAP was constructed by ligating a DraI-digested fragment of the above pGEM-TAP and a blunt-ended fragment of a NheI and AgeI-digested pLysSRARE2 (Novagen).
- Construction of Sequence Containing Nucleic Acids Corresponding to Fluorescent Protein-Encoding Gene
- (a) tagBFP
- A fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the pTAP-tagBFP as a template, and tagBFP fwd and TAP_IVTrev as primers in a solution of Table 8 as prepared in accordance with manufacturer's instructions.
-
TABLE 8 Component Final concentration 10xkod-plus-Neo buffer 1x 2 mM dNTPs 200 μM 25 mM MgSO4 aq 1.5 mM tagBFP fwd 0.3 μM TAP_IVTrev 0.3 μM pTAP-tagBFP 1.0 ng/μL 1 U/μL Kod+ polymerase 0.02 U/μL D2W Final volume 50 μL - The amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions (to yield what is called a tagBFP PCR product).
- (b) EGFP
- In the same manner as (a), a fragment was amplified by PCR using the pCTp-EGFP as a template and TAPEGFP_IVTfwd and TAP_IVTrev as primers. The PCR amplification was carried out and the resulting PCR product (called an EGFP PCR product) was purified.
- Construction of 5′UTR and 3′UTR Sequences
- (a) 5′UTR
- A fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the IVT_5prime_UTR, which is shown in Table 10, as a template, and TAP_T7_G3C fwd primer and Rev5UTR primer as primers in a solution of Table 9 as prepared in accordance with manufacturer's instructions.
-
TABLE 9 Component Final concentration 10xkod-plus-Neo buffer 1x 2 mM dNTPs 200 μM 25 mM MgSO4 aq 1.5 mM TAP_T7_G3C fwd primer 0.3 μM Rev5UTR primer 0.3 μM IVT_5prime_UTR 1.0 ng/μL 1 U/μL Kod+ polymerase 0.02 U/μL D2W Final volume 50 μL -
TABLE 10 olgo-DNA name Sequence (5′-3′) IVT_5prime_UTR CAGTGAATTGTAATACGACTCACTATAGGGCG AATTAAGAGAGAAAAGAAGAGTAAGAAGAAAT ATAAGACACCGGTCGCCACCATG IVT_3prime_UTR TCTAGACCTTCTGCGGGGCTTGCCTTCTGGCC ATGCCCTTCTTCTCTCCCTTGCACCTGTACCT CTTGGTCTTTGAATAAAGCCTGAGTAGG - The amplified PCR product was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions (to yield what is called a 5′UTR PCR product).
- (b) 3′UTR
- In the same manner as (a), a fragment was amplified by PCR using IVT_3 prime_UTR, which is shown in Table 10, as a template and Fwd3UTR primer and Rev3UTR2T20 as primers, and the resulting fragment was purified (to yield what is called a 3′UTR PCR product).
- IVT_EGFP Template Construction
- A fragment was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the above-described EGFP PCR product, 5′ UTR PCR product and 3′ UTR PCR product as templates, and TAP_T7_G3C fwd primer and 3UTR120A rev primer as primers in a solution of Table 11 as prepared in accordance with manufacturer's instructions.
-
TABLE 11 Component Final concentration 10xkod-plus-Neo buffer 1x 2 mM dNTPs 200 μM 25 mM MgSO4 aq 1.5 mM TAP_T7_G3C fwd primer 0.3 μM 3UTR120A rev primer 0.3 μM EGFP PCR product 0.2 ng/μL 5′UTR PCR product 10 nM 3′UTR PCR product 10 nM 1 U/μL Kod+ polymerase 0.02 U/μL D2W Final volume 50 μL - The amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions.
- Construction of IVT (In Vitro Transcription) Template for miRNA-Responsive mRNA
- The IVT template for an miRNA switch was amplified by PCR using KOD-Plus-Neo (KOD-401, TOYOBO), the above-described tagBFP PCR product, each miRNA target 5′UTR oligo-DNA, and the above-described 3′ UTR PCR product as templates, and T7FwdB primer and 3UTR120A rev primer as primers in a solution of Table 12 as prepared in accordance with manufacturer's instructions. Table 13 lists each miRNA target 5′ UTR oligo-DNA.
-
TABLE 12 Component Final concentration 10xkod-plus-Neo buffer 1x 2 mM dNTPs 200 μM 25 mM MgSO4 aq 1.5 mM T7FwdB primer 0.3 μM 3UTR120A rev primer 0.3 μM tagBFP PCR product 0.2 ng/μL miRNA target 5′UTR olgo-DNA 10 nM 3′UTR PCR product 10 nM 1 U/μL Kod+ polymerase 0.02 U/μL D2W Final volume 50 μL -
TABLE 13 oligo-DNA name Sequence 5UTRtemp_T208a-3p CGACTCACTATAGGTTCCGCGATCGCGGA TCCACAAGCTTTTTGCTCGTCTTATAGAT CACACCGGTCGCCACCATG 5UTRtemp_T10b-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCCACAAATTCGGTTCTACAGGGTAAGA TCCACCGGTCGCCACCATG 5UTRtemp_T126-3p CGACTCACTATAGGTTCCGCGATCGCGGA TCCCGCATTATTACTCACGGTACGAAGAT CACACCGGTCGCCACCATG 5UTRtemp_T126a-5p CGACTCACTATAGGTTCCGCGATCGCGGA atog TCCCGCGTACCAAAAGTAATAGTGAGATC AACACCGGTCGCCACCATG 5UTRtemp_T196b-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCCCCAACAACAGGAAACTACCTAAGAT CACACCGGTCGCCACCATG 5UTRtemp_T216a-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCTCACAGTTGCCAGCTGAGATTAAGAT CACACCGGTCGCCACCATG 5UTRtemp_T126-3p + CGACTCACTATAGGTTCCGCGATCGCGGA T208a-3p TCCCGCATTATTACTCACGGTACGAACAA GCTTTTTGCTCGTCTTATAGATCACACCG GTCGCCACCATG 5UTRtemp_T126-5p + CGACTCACTATAGGTTCCGCGATCGCGGA T208a-3p TCCCGCGTACCAAAAGTAATAGTGAACAA GCTTTTTGCTCGTCTTATAGATCACACCG GTCGCCACCATG 5UTRtemp_208a- CGACTCACTATAGGTTCCGCGATCGCGGA 3p +T126-3p TCCACAAGCTTTTTGCTCGTCTTATCGCA TTATTACTCACGGTACGAAGATCACACCG GTCGCCACCATG 5UTRtemp_T208a- CGACTCACTATAGGTTCCGCGATCGCGGA 3p + T126-5p TCCACAAGCTTTTTGCTCGTCTTATCGCG TACCAAAAGTAATAGTGAAGATCACACCG GTCGCCACCATG 5UTRtemp_T122-3p CGACTCACTATAGGTTCCGCGATCGCGGA TCCATATTTAGTGTGATAATGGCGTTAGA TCCACCGGTCGCCACCATG 5UTRtemp_T122-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCCAAACACCATTGTCACACTCCAAGAT CACACCGGTCGCCACCATG 5UTRtemp_T192-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCGGCTGTCAATTCATAGGTCAGAGATC AACACCGGTCGCCACCATG 5UTRtemp_T194-5p CGACTCACTATAGGTTCCGCGATCGCGGA TCCTCCACATGGAGTTGCTGTTACAAGAT CACACCGGTCGCCACCATG 5UTRtemp_T215 CGACTCACTATAGGTTCCGCGATCGCGGA TCCGTCTGTCAATTCATAGGTCATAGATC AACACCGGTCGCCACCATG 5UTRtemp_T375 CGACTCACTATAGGTTCCGCGATCGCGGA TCCTCACGCGAGCCGAACGAACAAAAGAT CACACCGGTCGCCACCATG - The amplified PCR product was digested by DpnI (TOYOBO) at 37° C. for 30 min, and was then purified using a MiniElute PCR purification kit (QIAGEN) in accordance with manufacturer's instructions.
- Synthesize and Production of mRNA
- Each mRNA was produced using a MEGAscript T7 kit (Ambion) and each IVT template in accordance with the protocol described in Warren L, et al., Cell Stem Cell. 7(5): 618-30 (2010). In this reaction, pseudouridine-5′-triphosphate and methylcytidine-5′-triphosphate (TriLink BioTechnologies) were used as alternatives for uridine triphosphate and cytidine triphosphate, respectively. Before the IVT (mRNA synthesis) reaction, guanidine-5′-triphosphate was diluted five-fold with Anti-Reverse Cap Analog (New England Biolabs). The reaction mixture was incubated at 37° C. for 5 h, TURBO DNase (Ambion) was added, and the resulting mixture was then further incubated at 37° C. for 30 min. The resulting mRNA was purified through FavorPrep Blood/Cultured Cells total RNA extraction column (Favorgen Biotech), and was incubated with Antarctic phosphatase (New England Biolabs) at 37C° for 30 min. After that, the mRNA was further purified using an RNeasy Mini Elute Cleanup kit (QIAGEN).
- Endothelial Cell Isolation
- HUVECs Culture
- Human umbilical vein endothelial cells (HUVECs) (C2517A) were purchased from Lonza, Inc., and were cultured using an EGM-2 Endothelial Cell Growth Medium-2 Bullet kit (Lonza).
- Microarray Analysis
- The miRNA expression was profiled using Agilent Technologies Human miRNA Microarray Release 19.0 in accordance with the manufacturer's protocol. The data was analyzed using GeneSpring GX 12.6 software (Agilent Technologies).
- Method for Inducing Cardiomyocytes Containing Endothelial Cells
- As human iPS cells, used was 201B7 cell line described in Takahashi K, et al. Cell. 131: 861-72, 2007, 409B2 (available from Riken BioResource Center), or 606A1 described in Okita K, et al., Stem Cells 31, 458-66, 2012. As human ES cells, KhES1 was used and obtained from Kyoto University. The human iPS cells or ES cells were treated with CTK solution (ReproCELL) for 2 min. Next, the solution was removed. Subsequently, the cells were treated with Accumax (Innovative Cell Technologies) for 5 min. Then, the cells were subjected to pipetting to single cells. The resulting cells were recovered by centrifugation, transferred to a low-attachment 6-well dish (Corning), and cultured at 37° C. under 5% oxygen condition in 1.5 ml/well of STEMPRO 34 (Invitrogen) supplemented with 2 mM L-glutamine, 150 μg/mL transferrin, 50 μg/mL ascorbic acid (sigma), 4×10−4 M monothioglycerol (MTG), 0.5% penicillin/streptomycin (Invitrogen), 10 μM ROCK inhibitor (Y-27632), and 2 ng/mL BMP4 (R&D) to induce EB formation (day 0). Next day (day 1), to the 6-well plate wells having an EB culture was added an equal volume of STEMPRO 34 supplemented with 2 mM L-glutamine, 150 μg/mL transferrin, 50 μg/mL ascorbic acid, 4×10−4 M MTG, 0.5% penicillin/streptomycin, 18 ng/mL BMP4 (at final concentration of 10 ng/ml), 10 ng/mL bFGF (at final concentration of 5 ng/ml), and 12 ng/mL Activin A (at final concentration of 6 ng/ml). The resulting culture was cultured at 37° C. under 5% oxygen condition for 3 days. Four days after the induction (day 4), the resulting EB was washed with IMDM (Invitrogen). To the dish was added STEMPRO 34 supplemented with 2 mM L-glutamine, 150 μg/mL transferrin, 50 μg/mL ascorbic acid, 4×10−4 M MTG, 10 ng/mL VEGF, and 1 μM IWP-3 (Stemgent). The resulting culture was cultured at 37° C. under 5% oxygen condition for 4 days. Eight days after the induction (day 8), the medium was changed to STEMPRO 34 supplemented with 2 mM L-glutamine, 150 μg/mL transferrin, 50 μg/mL ascorbic acid, 4×10−4 M MTG, 0.5% penicillin/streptomycin, 10 ng/mL VEGF, and 5 ng/mL bFGF. The resulting culture was cultured at 37° C. under 5% oxygen condition for 4 days. At this occasion, the medium change under the same conditions was performed once every two days. Twelve days after the induction (day 12), the culture was transferred to an incubator with a normal oxygen level and was further cultured for 8 days. At this occasion, the medium change under the same conditions was performed once every two days.
- Tube Formation Assay
- The endothelial cells isolated were seeded at 2×105 cells/well on a Matrigel (BD)-coated 24-well plate, and were cultured in EGM-2 Bullet Kit medium. Next day, the culture was observed under a Biorevo BZ-9000 microscope.
- Results
- To isolate endothelial cells, human umbilical vein endothelial cells (HUVECs) were used for microarray analysis; and top 5 miRNAs (hsa-miR-10b-5p, hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-196b-5p, and hsa-miR-216a-5p) specifically expressed in the endothelial cells were discovered (
FIG. 1A ). Next, miRNA switches, each having BFP and a sequence specifically recognized by each miRNA, (hereinafter, each referred to as miR-** miRNA switch) were constructed by the procedure described in Example 1 and each miRNA switch together with EGFP mRNA as a control was introduced into HUVECs. As a result, HUVECs of interest were successfully isolated using each of miR-126-3p miRNA switch and miR-126-5p miRNA switch (FIG. 1B ). As a control, both BFP mRNA and EGFP mRNA were together introduced into HUVECs. This result was compared with the above result and the isolation was verified. Further, to check whether or not the miRNA switches were used to be able to isolate endothelial cells, the above protocol was applied to cardiomyocyte induction. Then, examined was whether it was possible to isolate endothelial cells contained in cells after the induction. The results demonstrated that a post-cardiomyocyte-induction cell population contained about 5 to 10% of cells capable of being isolated using the miR-126-3p miRNA switch and the miR-126-5p miRNA switch and the cells were positive for CD31, an endothelial marker (FIGS. 2A and 2B ). By contrast, CD31-positive cells were unable to be isolated using miR-208a miRNA switch. Hence, it is suggested that the miR-126-3p miRNA switch and the miR-126-5p miRNA switch are useful in isolating endothelial cells from a heterogeneous cell population. Further, the cells that were isolated using the miR-126-5p miRNA switch were subjected to tube formation assay. The results demonstrated that the cells had angiogenic potential (FIG. 2C ). - Next examined was whether or not cardiomyocytes and endothelial cells were able to be simultaneously isolated using an miRNA switch having sequences specificity recognized by two miRNAs specific to cardiomyocytes and endothelial cells. Specifically, 4 different miRNA switches, in which miR-208a, and miR-126-3p or miR-126-5p were used in combination, as described in
FIG. 3A were constructed; each miRNA switch together with EGFP mRNA as a control was introduced into a cell population containing cardiomyocytes induced from iPS cells; and the fluorescent intensity of BFP, the percentage of CD31-positive cells, and the percentage of cTnT-positive cells were measured. The results demonstrated that cells positive for each marker were successfully isolated (FIGS. 3B and 3C ). In addition, at that time, when a combination of miR-126-5p+miR-208a was used, a decrease in the level of fluorescent intensity of BFP was relatively strong. - Hepatocyte Isolation
- Hepatocytes Culture
- Human primary hepatocytes were purchased from Bioreclamation IVT and were cultured in InVitroGRO CP Medium (Bioreclamation IVT) supplemented with Torpedo Antibiotic Mix (Bioreclamation IVT).
- Method for Inducing Hepatocytes
- As human iPS cells, used was 201B6 cell line described in Takahashi K, et al., Cell. 131: 861-72, 2007. Hepatocytes were induced from human iPS cells in accordance with the method, with a modification, described in Kajiwara M, et al., Proc Natl Acad Sci USA. 109: 12538-12543, 2012. Specifically, the human iPS cells were seeded on a Matrigel-coated plate. Next, to the plate was added RPMI 1640 medium supplemented with 1×B27 supplement, 100 ng/ml activin A, 10 μM Y-27632, and 1 μM CHIR99021. The next day (day 1), the medium was changed to a culture medium in which Y-27632 had been removed from and 0.5 mM NaB had been added to the above medium. On day 5, the medium was changed to knockout DMEM supplemented with 20% knockout serum replacement (KSR), 1 mM L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, 1% DMSO, 10 ng/ml FGF, and 20 ng/ml BMP4, and the cells were cultured for 6 days. On day 11, the medium was changed to hepatocyte culture medium (Lonza) supplemented with 20 ng/ml hepatocyte growth factor (HGF) and 20 ng/ml oncostatin M (OSM). The culture mixture was further cultured for seven days to yield hepatocytes.
- Results
- To isolate hepatocytes, primary hepatocytes were used for microarray analysis; and top 5 miRNAs (hsa-miR-122-3p, hsa-miR-122-5p, hsa-miR-192-5p, hsa-miR-194-5p, and hsa-miR-215) specifically expressed in hepatocytes were discovered (
FIG. 4A ). Corresponding miRNA switches were constructed by the procedure of Example 1 and each miRNA switch together with EGFP mRNA as a control is introduced into hepatocytes derived from induced differentiation of human iPS cells. As a result, cells of interest were successfully isolated using miR-122-5p miRNA switch (FIG. 4B ). Then, it was examined as to whether ALBUMIN and HNF4A were expressed in the cells isolated. The results demonstrated that the cells positive for both could be isolated (FIGS. 5A and 5B ). Further, the cells that were isolated using miR-122-5p as an indicator were confirmed to be positive for ALBUMIN by immunostaining (FIG. 5C ). - Insulin-Producing Cell Isolation
- Method for Inducing Insulin-Producing Cells
- As human iPS cells, used was 585A1 cell line described in Okita K, et al., Stem Cells 31, 458-66, 2012. Insulin-producing cells were induced from human iPS cells in accordance with the process described in Kunisada Y, et al., Stem Cell Res. 8:274-284, 2012 and Nakagawa, M, et al., Sci Rep 4, 3594, 2014. Specifically, the cells were cultured for 1 day in RPMI 1640 medium supplemented with 1×B27 supplement, 10 μM Y-27632, and 3 μM CHIR99021. The next day (day 1), the medium was changed to RPMI 1640 medium containing 1×B27 supplement, 100 ng/ml activin A, and 1 μM CHIR99021, and the cells were cultured for 3 days. Subsequently, the medium was changed to Improved MEM Zinc Option medium supplemented with 0.5×B27 supplement, 1 μM dorsomorphin, 2 μM retinoic acid, and 10 μM SB431542, and the cells were cultured for 6 days. Further, the medium was changed to Improved MEM Zinc Option medium supplemented with 0.5×B27 supplement, 10 μM forskolin, 10 μM dexamethasone, 5 μM Alk5 inhibitor II, and 10 mM nicotinamide, and the cells were cultured for 8 days.
- Results
- According to the previous reports (Francis, N., et al., Microrna 3, 54-63, 2014; Lahmy, R., et al., Mol Biol Rep 41, 2055-2066, 2014; and Ozcan, S. Mol Endocrinol 28, 1922-1933, 2014), has-miR-375 was used as an miRNA specifically expressed in insulin-producing cells. First, miR-375 miRNA switch was constructed by the above procedure and the miR-375 miRNA switch together with EGFP mRNA as a control was introduced into insulin-producing cells derived from induced differentiation of human iPS cells. As a result, cells of interest were successfully isolated using the miRNA switch (
FIGS. 6A and 6B ). The cells isolated were confirmed to be positive for INSULIN by immunostaining (FIG. 6C ).
Claims (6)
1-11. (canceled)
12. A method for producing hepatocytes, comprising:
(a) producing, from a pluripotent stem cell, a cell population containing hepatocytes;
(b) introducing, into the cell population of the step (a), an miRNA-responsive mRNA consisting of sequences comprising (i) a nucleic acid recognized specifically by miR-122-5P and (ii) a nucleic acid corresponding to a coding region of a first marker gene, wherein the miRNA-responsive mRNA is introduced into the cell population in a form of a synthetic RNA molecule; and
(c) sorting a cell having a low level of translation of the first marker gene of the step (b).
13. (canceled)
14. The method according to claim 12 , wherein the miRNA-responsive mRNA comprises a nucleic acid sequence having (i) and (ii) linked in a 5′ to 3′ direction.
15. The method according to claim 12 , wherein the first marker gene of (ii) is one or more genes selected from the group consisting of a fluorescent protein-encoding gene, an apoptosis-inducing gene, and a suicide gene.
16. The method according to claim 12 , further comprising introducing, into the cell population, an mRNA consisting of a sequence comprising a nucleic acid corresponding to a coding region of a second marker gene, wherein a cell in which the second marker gene is translated is sorted as the cell of interest, and wherein the second marker gene is a fluorescent protein-encoding gene different from the first marker gene, or a drug resistance gene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/660,333 US20200056248A1 (en) | 2015-04-22 | 2019-10-22 | Method for sorting tissue cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015087805 | 2015-04-22 | ||
JP2015087805 | 2015-04-22 | ||
PCT/JP2016/062710 WO2016171235A1 (en) | 2015-04-22 | 2016-04-22 | Method for sorting tissue cells |
US201715568209A | 2017-12-01 | 2017-12-01 | |
US16/660,333 US20200056248A1 (en) | 2015-04-22 | 2019-10-22 | Method for sorting tissue cells |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,209 Division US10501811B2 (en) | 2015-04-22 | 2016-04-22 | Method for sorting tissue cells |
PCT/JP2016/062710 Division WO2016171235A1 (en) | 2015-04-22 | 2016-04-22 | Method for sorting tissue cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200056248A1 true US20200056248A1 (en) | 2020-02-20 |
Family
ID=57143175
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,209 Active US10501811B2 (en) | 2015-04-22 | 2016-04-22 | Method for sorting tissue cells |
US16/660,333 Abandoned US20200056248A1 (en) | 2015-04-22 | 2019-10-22 | Method for sorting tissue cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,209 Active US10501811B2 (en) | 2015-04-22 | 2016-04-22 | Method for sorting tissue cells |
Country Status (4)
Country | Link |
---|---|
US (2) | US10501811B2 (en) |
EP (1) | EP3318630B1 (en) |
JP (1) | JP6960159B6 (en) |
WO (1) | WO2016171235A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12012602B2 (en) | 2017-03-10 | 2024-06-18 | The Medical College Of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3121276B1 (en) * | 2014-03-20 | 2019-04-17 | Kyoto University | Cardiomyocyte sorting method |
WO2019013294A1 (en) * | 2017-07-12 | 2019-01-17 | 国立大学法人京都大学 | HIGH EXPRESSION mRNA SWITCH |
WO2019031595A1 (en) * | 2017-08-10 | 2019-02-14 | 国立大学法人京都大学 | Method for screening neural progenitor cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5405312B2 (en) | 2007-11-22 | 2014-02-05 | 独立行政法人科学技術振興機構 | Translation control system in cell or artificial cell model with small RNA |
CN102186483A (en) | 2008-08-11 | 2011-09-14 | 德克萨斯大学系统董事会 | A micro-rna that promotes vascular integrity and uses thereof |
SI2424571T1 (en) | 2009-04-30 | 2020-10-30 | Ospedale San Raffaele S.R.L. | Gene vector |
WO2011154553A2 (en) * | 2010-06-11 | 2011-12-15 | Cellartis Ab | Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
JP5971599B2 (en) | 2011-08-23 | 2016-08-17 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Restricted growth adenovirus |
US20140200261A1 (en) * | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
-
2016
- 2016-04-22 EP EP16783256.7A patent/EP3318630B1/en active Active
- 2016-04-22 WO PCT/JP2016/062710 patent/WO2016171235A1/en active Application Filing
- 2016-04-22 JP JP2017514194A patent/JP6960159B6/en active Active
- 2016-04-22 US US15/568,209 patent/US10501811B2/en active Active
-
2019
- 2019-10-22 US US16/660,333 patent/US20200056248A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12012602B2 (en) | 2017-03-10 | 2024-06-18 | The Medical College Of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
Also Published As
Publication number | Publication date |
---|---|
EP3318630A1 (en) | 2018-05-09 |
EP3318630A4 (en) | 2019-04-24 |
EP3318630B1 (en) | 2020-11-04 |
US10501811B2 (en) | 2019-12-10 |
JP6960159B6 (en) | 2022-06-24 |
JP6960159B2 (en) | 2021-11-05 |
JPWO2016171235A1 (en) | 2018-02-15 |
WO2016171235A1 (en) | 2016-10-27 |
US20180100203A1 (en) | 2018-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6745498B2 (en) | Pluripotent stem cells for inducing neural differentiation | |
US20200056248A1 (en) | Method for sorting tissue cells | |
KR102320537B1 (en) | New method for inducing dopamine-producing neural precursor cells | |
JP6612736B2 (en) | Cardiomyocyte sorting method | |
JP6883791B2 (en) | How to select skeletal muscle progenitor cells | |
EP2938721B1 (en) | Method for inducing astrocytes | |
JP7236738B2 (en) | Method for sorting neural progenitor cells | |
US10689624B2 (en) | Compound for identifying pluripotent cells | |
JP6877752B2 (en) | Method for identifying intracellular proteins | |
WO2022102742A1 (en) | Cell surface marker for high efficiency purification of skeletal muscle lineage cells and skeletal muscle stem cells, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |